- Approval Id
- 6c7d35cbbc05ca06
- Drug Approval Emc Name
- Libmeldy
- Drug Name
- Libmeldy
- Company Name
- Orchard Therapeutics
- Company Address
- 245 Hammersmith Road, London, W6 8PW, UK
- Company Website
- https://orchard-tx.uk/
- Company Telephone
- +44 (0) 203 808-8286
- Company Medical Info Email
- medinfo@orchard-tx.com
- Atc Code
- A16AB21
- Legal Category
- Prescription only medicine
- Authorisation Holder
- Orchard Therapeutics (Europe) Limited
245 Hammersmith Road
London
W6 8PW
- Authorisation Number
- PLGB 49055/0002
- Authorisation Date
- 01/01/2021
- Instruction Authorisation Holder
- Orchard Therapeutics (Europe) Limited
245 Hammersmith Road
London
W6 8PW
- Instruction Authorisation Number
- PLGB 49055/0002
- Instruction Authorisation Date
- 01/01/2021
- Instruction Dosage Form
- Dispersion for infusion.
A clear to slightly cloudy, colourless to yellow or pink dispersion.
- Instruction Clinical Particulars
- 4.1 Therapeutic indications
Libmeldy is indicated for the treatment of metachromatic leukodystrophy (MLD) characterized by biallelic mutations in the arylsulfatase A (ARSA) gene leading to a reduction of the ARSA enzymatic activity:
- in children with late infantile or early juvenile forms, without clinical manifestations of the disease,
- in children with the early juvenile form, with early clinical manifestations of the disease, who still have the ability to walk independently and before the onset of cognitive decline (see section 5.1).4.2 Posology and method of administration
Libmeldy must be administered in a qualified treatment centre by a physician with experience in Haematopoietic Stem Cell Transplantation (HSCT) and trained for administration and management of patients treated with the medicinal product.
\*\*Posology\*\*
Libmeldy is intended for autologous use (see section 4.4) and should only be administered once.
The dose of Libmeldy must be determined based on the patient's body weight at the time of infusion.
Treatment consists of a single dose for infusion containing a dispersion of viable CD34+ cells in one or more infusion bags.
The minimum recommended dose of Libmeldy is 3 × 106 CD34+ cells/kg of body weight. In clinical studies, doses up to 30 × 106 CD34+ cells/kg have been administered.
The maximum volume of Libmeldy to be administered should remain < 20% of the patient's estimated plasma volume (see section 4.4 and section 6.6).
See the accompanying Lot Information Sheet (LIS) for additional information pertaining to dose.
\*Peripheral blood mobilisation and apheresis\*
The autologous CD34+ cells are isolated from mobilised peripheral blood (mPB). This is achieved by apheresis procedure(s) following peripheral blood mobilisation.
For manufacture of Libmeldy, the patient must be able to donate a minimum of 8-10 ×106 CD34+ cells/kg, considering that the optimal range is between 20-30 × 106 CD34+ cells/kg.
The minimum CD34+ cell quantity may be achieved using one or more cycles of apheresis.
If, after medicinal product manufacturing, the minimum dose of Libmeldy of 3 × 106 CD34+ cells/kg is not achieved, the patient may undergo a further mobilisation protocol with one or more cycles of apheresis, in order to obtain more cells for additional manufacture (see \*Mobilisation and apheresis\* in section 5.1).
A back-up collection of HSPC containing at least 2 x 106 CD34+ cells/kg is also required for use as rescue treatment should the quality of Libmeldy be compromised after initiation of myeloablative conditioning and before Libmeldy infusion, failure of primary engraftment, or prolonged bone marrow aplasia after treatment with Libmeldy (see section 4.4).
These cells must be collected from the patient and be cryopreserved according to institutional procedures prior to myeloablative conditioning. The back-up cells may be harvested either through mPB apheresis or bone marrow harvest.
\*Peripheral blood mobilisation\*
Patients are required to undergo HSPC mobilisation with Granulocyte colony-stimulating factor (G-CSF) with or without plerixafor followed by apheresis to obtain CD34+ stem cells for medicinal product manufacturing (see section 5.1 for a description of the mobilisation regimen used in clinical studies).
\*\*Pre-treatment conditioning\*\*
The treating physician should confirm that autologous HSPC gene therapy administration is clinically appropriate for the patient before myeloablative conditioning is initiated (see section 4.4).
A myeloablative conditioning is required before infusion of Libmeldy to promote efficient engraftment of the genetically modified autologous CD34+ cells (see section 5.1 for a description of the myeloablative regimen used in clinical studies).
Busulfan is the recommended conditioning medicinal product.
Myeloablative conditioning should not begin until the complete set of infusion bag(s) constituting the dose of Libmeldy has been received and stored at the qualified treatment centre, and the availability of the back-up collection is confirmed.
Concurrently with the conditioning regimen, and prior to treatment with Libmeldy, it is recommended that patients receive prophylaxis for veno-occlusive disease (VOD) and related endothelial injury complications i.e. transplant-associated thrombotic microangiopathy (TA-TMA) or atypical haemolytic uremic syndrome (aHUS), in line with local guidelines.
Depending on the myeloablative conditioning regimen administered, prophylaxis for seizures should also be considered. Phenytoin is not recommended as it may increase busulfan clearance.
Prophylactic and empiric use of anti-infectives (bacterial, fungal, viral) should be considered for the prevention and management of infections especially during the neutropenic period following conditioning. Routine monitoring of most common viruses subject to re-activation is recommended as per local guidelines. Infection control measures and isolation procedures should be employed during the hospitalization according to local standards.
\*\*Pre-medication\*\*
It is recommended that pre-medication with intravenous chlorpheniramine (0.25 mg/kg, max. dose 10 mg), or equivalent medicinal products, be administered 15-30 minutes before the infusion of Libmeldy to reduce the possibility of an infusion reaction.
\*\*Special populations\*\*
\*Elderly\*
Libmeldy has not been studied in patients >65 years of age.
\*Renal impairment\*
Libmeldy has not been studied in patients with renal impairment. Patients should be assessed for renal impairment to ensure autologous HSPC gene therapy administration is appropriate. No dose adjustment is required.
\*Hepatic impairment\*
Libmeldy has not been studied in patients with hepatic impairment. Patients should be assessed for hepatic impairment to ensure autologous HSPC gene therapy administration is appropriate. No dose adjustment is required.
\*Paediatric population\*
The safety and efficacy of Libmeldy have not yet been established in patients with the late juvenile form of the disease (i.e. with a typical onset after 7 years of age). No data are available.
\*\*Method of administration\*\*
Libmeldy is for intravenous infusion only.
\*Precautions to be taken before handling or administering the medicinal product\*
This medicinal product contains genetically modified human cells. Healthcare professionals should therefore take appropriate precautions (wearing gloves and glasses) to avoid potential transmission of infectious diseases when handling the product.
For instructions on preparation, accidental exposure and disposal of Libmeldy, see section 6.6.
\*Preparation for infusion\*
Before administration, it must be confirmed that the patient's identity matches the unique patient information on the Libmeldy infusion bag(s) and accompanying documentation. The total number of infusion bags to be administered must also be confirmed with the patient specific information on the Lot Information Sheet (LIS) (see section 4.4).
The timing of thaw and infusion of Libmeldy should be coordinated. The infusion start time should be confirmed in advance and adjusted for thaw so that Libmeldy is available for infusion when the patient is ready. To maintain product viability, as soon as thawing is complete, it is recommended that Libmeldy be administered immediately. Administration must be completed within 2 hours from the time of thawing.
\*Administration\*
Administer the product as an intravenous infusion via a central venous catheter. When more than one bag of Libmeldy is needed, only one bag of medicinal product should be infused per hour. Each bag should be infused at an infusion rate which does not exceed 5 mL/kg/h, within approximately 30 minutes. The recommended administration set consists of a blood transfusion set equipped with a 200µm filter (see section 6.6).
For detailed instructions on preparation, administration, accidental exposure and disposal of Libmeldy, see section 6.6.4.3 Contraindications
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Previous treatment with haematopoietic stem cells gene therapy.
Contraindications to the mobilisation and the myeloablative medicinal products must be considered.4.4 Special warnings and precautions for use
\*\*Traceability\*\*
The traceability requirements of cell-based advanced therapy medicinal products must apply. To ensure traceability, the name of the product, the batch number and the name of the treated patient must be kept for a period of 30 years after expiry date of the product.
\*\*Autologous use\*\*
Libmeldy is intended solely for autologous use and must not, under any circumstances be administered to other patients. Libmeldy must not be administered if the information on the product labels and Lot Information Sheet (LIS) do not match the patient's identity.
\*\*Rapidly progressive phase of the disease\*\*
Treatment with Libmeldy should be performed before the disease enters its rapidly progressive phase.
Eligibility to treatment with Libmeldy should initially be assessed by the treating physician via full neurological examination, motor function assessment and neurocognitive assessment, as appropriate for the patients' age.
Prior to the commencement of cellular harvest, the treating physician should ensure that the patient has not clinically deteriorated. Thereafter, prior to the commencement of conditioning, the treating physician should ensure that autologous HSPC gene therapy administration remains clinically appropriate for the patient, and that treatment with Libmeldy is still indicated.
\*\*Mobilisation and myeloablative conditioning medicinal products\*\*
Warnings and precautions of the mobilisation and myeloablative conditioning medicinal products must be considered.
\*\*Central venous catheter (CVC) complications including infections and thromboses\*\*
Infections related to the use of CVCs have been reported in clinical studies and there is a risk of thrombosis associated with the CVC. Patients should be closely monitored for potential infections and catheter-related events.
\*\*Transmission of an infectious agent\*\*
Although Libmeldy is tested for sterility and mycoplasma, a risk of transmission of infectious agents exists. Healthcare professionals administering Libmeldy should therefore monitor patients for signs and symptoms of infections after treatment and treat appropriately, if needed.
\*\*Interference with virology testing\*\*
Due to limited and short spans of identical genetic information between the lentiviral vector used to create Libmeldy and HIV, some HIV nucleic acid tests (NAT) may give a false positive result.
Patients who have received Libmeldy should not be screened for HIV infection using a PCR-based assay.
\*\*Blood, organ, tissue and cell donation\*\*
Patients treated with Libmeldy should not donate blood, organs, tissues and cells for transplantation. This information is provided in the Patient Alert Card which must be given to the patient after treatment.
\*\*Hypersensitivity and infusion-related reactions\*\*
Serious hypersensitivity reactions, including anaphylaxismay be due to dimethylsulfoxide (DMSO) in Libmeldy. Patients not previously exposed to DMSO should be observed closely. Vital signs (blood pressure, heart rate, and oxygen saturation) and the occurrence of any symptom should be monitored prior to the start of the infusion, approximately every ten minutes during the infusion and every hour, for 3 hours, after the infusion.
When more than one bag of Libmeldy is needed, it should be ensured prior to infusion that the volume of medicinal product to be infused is compatible with the recommended limit of DMSO, i.e. the total volume of DMSO administered should remain <1% of the patient's estimated plasma volume. The maximum volume of Libmeldy to be administered should therefore remain < 20% of the patient's estimated plasma volume (see section 6.6).
Also, when more than one bag of Libmeldy is needed, only one bag of medicinal product should be infused per hour.
\*\*Engraftment failure\*\*
In clinical studies, no patients failed to engraft bone marrow, as measured by neutrophil count in peripheral blood. Failure of neutrophil engraftment is a short-term but potentially important risk, defined as failure to reach an absolute neutrophil count (ANC) >500 cells/μL associated with no evidence of bone marrow recovery (i.e. hypocellular marrow) by day 60 after Libmeldy infusion. In case of engraftment failure, the non-transduced back-up stem cells should be infused according to local standards (see section 4.2).
\*\*Prolonged cytopenia\*\*
Patients may exhibit severe cytopenias, including severe neutropenia [defined as Absolute Neutrophil Count (ANC) <500 cells/μL] and prolonged thrombocytopenia, for several weeks following myeloablative conditioning and Libmeldy infusion. In clinical studies, haematological recovery after conditioning with busulfan was typically seen four to five weeks from the day of infusion of Libmeldy. In the clinical study with the cryopreserved (commercial) formulation, neutrophil engraftment occurred after a median (min, max) of 36.5 (31-40) days after gene-therapy. Patients should, therefore, be monitored for signs and symptoms of cytopenia for at least 6 weeks after infusion.
Red blood cells should be monitored according to medical judgment until engraftment of these cells and recovery are achieved. Supportive transfusion of red cells and platelets should be given according to medical judgement and institutional practice. Blood cell count determination and other appropriate testing should be promptly considered whenever clinical symptoms suggestive of anaemia arise.
If cytopenia persists beyond six to seven weeks, despite the use of granulocyte mobilising medicinal products, the non-transduced back up stem cells should be infused. If cytopenia persists despite infusion of non-transduced back-up stem cells, alternative treatments should be considered.
\*\*Delayed platelet engraftment\*\*
Platelet engraftment is defined as the first of 3 consecutive days with platelet values ≥ 20 x 109/L obtained on different days after Libmeldy infusion, with no platelet transfusion administered for 7 days immediately preceding and during the evaluation period (up to 60 days post gene therapy).
During the clinical development, 4/35 patients (11.4%) reported delayed platelet engraftment (median: 73.5 days, range 65-109 days) which was not correlated with an increased incidence of bleeding. As part of the standard of care/prophylaxis, all patients in the integrated safety set (N=29) received transfusion support with platelets. Platelets counts should be monitored according to medical judgment until engraftment of these cells and recovery is achieved. Supportive transfusion of platelets should be given according to medical judgement and institutional practice.
\*\*Metabolic acidosis\*\*
Prior to a treatment with Libmeldy, the presence of renal tubular acidosis should be evaluated alongside risks of the conditioning medicinal product and risks of the gene therapy procedure, which may contribute to the development of metabolic acidosis. Acid-base status should be monitored throughout conditioning and until the patient is no longer under metabolic stress. The treating physician should consider sodium bicarbonate replacement alongside any other required treatment and should aim to correct any concurrent adverse reaction(s) that might contribute to metabolic acidosis.
\*\*Thyroid monitoring\*\*
Transient increases in thyroid stimulating hormone (TSH), free T4 (FT4; thyroxine) and free T3 (FT3; tri-iodothyronine) were observed in some patients during clinical studies. Considering that thyroid disorders could potentially be masked by critical illness or induced by concomitant medication, patients should be assessed for thyroid function and structure prior to treatment with Libmeldy. Thyroid function and structure should also be monitored in the short term after treatment, and as necessary thereafter.
\*\*Risk of insertional oncogenesis\*\*
There is a theoretical risk of leukaemia or lymphoma after treatment with Libmeldy. In the event that leukaemia or lymphoma is detected in any patient who received Libmeldy, blood samples should be collected for integration site analysis.
\*\*Anti-ARSA antibodies\*\*
During clinical development, anti-ARSA antibodies (AAA) were reported in 5 patients. Titers were generally low and resolved spontaneously or after treatment with rituximab (see section 4.8). No impacts on the clinical efficacy or safety outcomes were observed.
Monitoring of AAA is recommended prior to treatment, between 1 and 2 months after gene therapy, and then at 6 months, 1 year, 3 years, 5 years, 7 years, 9 years, 12 years, 15 years post treatment.
In a case of disease onset or significant disease progression, additional AAA monitoring is recommended.
\*\*Serological testing\*\*
Libmeldy has not been studied in patients with HIV-1, HIV-2, HTLV-1, HTLV-2, HBV, HCV or mycoplasma infection.
All patients should be tested for HIV-1/2, HTLV-1/2, HBV, HCV and mycoplasma prior to mobilisation to ensure acceptance of the cellular source material for Libmeldy manufacturing.
\*\*Anti-retroviral use\*\*
Patients should not take anti-retroviral medicinal products from at least one month prior to mobilisation until at least 7 days after Libmeldy infusion (see section 4.5). If a patient requires anti-retrovirals following exposure to HIV/HTLV, initiation of Libmeldy treatment should be delayed until an HIV/HTLV western blot and viral load assay have been performed at 6 months post-exposure.
\*\*After Libmeldy administration\*\*
After the infusion, standard procedures for patient management after HSPC \*\*transplantation\*\* should be followed.
Immunoglobulin G should be maintained above 5g/L to prevent potential late \*\*infections\*\* (occurring later than 100 days post therapy) associated with severe hypogammaglobinaemia, resulting from apheresis and conditioning.
Any blood products required within the first 3 months after Libmeldy infusion should be irradiated.
\*\*Long-term follow-up\*\*
Patients are expected to be enrolled in a long-term follow-up scheme in order to better understand the long-term safety and efficacy of Libmeldy.
\*\*Sodium content\*\*
This medicinal product contains 35 – 560 mg sodium per dose, which is equivalent to 2 to 28% of the WHO recommended maximum daily intake of 2 g sodium for an adult.4.5 Interaction with other medicinal products and other forms of interaction
No interaction studies have been performed.
The nature of Libmeldy is such that no pharmacokinetic interactions are expected with other medicinal products.
Patients should not take anti-retroviral medicinal products from at least one month \*\*prior\*\* to mobilisation until at least 7 days after Libmeldy infusion (see section 4.4).
\*\*Live vaccines\*\*
The safety of immunisation with live viral vaccines during or following treatment with Libmeldy has not been studied. As a precautionary measure, vaccination with live vaccines is not recommended for at least 6 weeks prior to the start of myeloablative conditioning, during Libmeldy treatment, and until haematological recovery following treatment.4.6 Fertility, pregnancy and lactation
As Libmeldy is not intended for use in adults, human data on use during pregnancy or lactation and animal reproduction studies are not available.
With regard to fertility, consult the SmPC of the myeloablative conditioning medicinal product. It should be noted that the treating physician should inform the patient's parents/carers about options for cryopreservation of spermatogonial stem cells or ovarian tissue.4.7 Effects on ability to drive and use machines
Not relevant.4.8 Undesirable effects
\*\*Summary of the safety profile\*\*
The safety of Libmeldy was evaluated in 35 patients with MLD.
The median duration of follow-up in the integrated safety data set, which included 29 patients treated with the fresh (investigational) formulation was 4.51 years (range: 0.64 to 8.85 years). Three patients died and a total of 26 patients remained in the follow-up phase.
The median duration of follow-up in the 6 patients treated with the cryopreserved (commercial) formulation was 0.87 years (range: 0.0 to 1.47 years). All of them remained in the follow-up phase (see section 5.1).
Given the small patient population, adverse reactions in the table below do not provide a complete perspective on the nature and frequency of these events.
Treatment with Libmeldy is preceded by medical interventions, namely haematopoietic stem cell collection peripheral blood mobilisation with G-CSF with or without plerixafor followed by apheresis, and myeloablative conditioning (preferably using busulfan), which carry their own risks. When assessing the safety of a treatment with Libmeldy, the safety profile and product information of the medicinal products used for peripheral blood mobilisation and myeloablative conditioning should be considered, in addition to the risks linked to the gene therapy.
\*\*Tabulated list of adverse reactions\*\*
Adverse reactions are listed by MedDRA body system organ class and by frequency. Frequencies are defined as: very common (≥1/10), and common (≥1/100 and <1/10).
\*\*Table 1 Adverse reactions attributed to Libmeldy\*\*
| | | |
| --- | --- | --- |
| \*\*System Organ Class\*\* | \*\*Very Common\*\* | \*\*Common\*\* |
| Immune system disorders | Antibody Test Positive (Anti ARSA Antibody) | |
\*\*Table 2 Adverse reactions potentially attributed to myeloablative conditioning\\*\*\*
| | | |
| --- | --- | --- |
| \*\*System Organ Class\*\* | \*\*Very Common\*\* | \*\*Common\*\* |
| Infections and infestations | | Cytomegalovirus viraemia, Pneumonia, Staphylococcal infection, Urinary tract infection, Viral infection |
| Blood and lymphatic system disorders | Febrile neutropenia, Neutropenia | Anaemia, Thrombocytopenia |
| Metabolism and nutrition disorders | Metabolic acidosis | Fluid overload |
| Psychiatric disorders | | Insomnia |
| Nervous system disorders | | Headache |
| Respiratory, thoracic and mediastinal disorders | | Epistaxis, Oropharyngeal pain |
| Gastrointestinal disorders | Stomatitis, Vomiting | Ascites, Diarrhoea, Gastrointestinal haemorrhage, Nausea |
| Hepatobiliary disorders | Hepatomegaly, Veno-occlusive liver disease | Hypertransaminasaemia |
| Skin and subcutaneous tissue disorders | | Skin exfoliation |
| Musculoskeletal and connective tissue disorders | | Back pain, Bone pain |
| Renal and urinary disorders | | Oliguria |
| Reproductive System and Breast Disorders | Ovarian failure | |
| General disorders and administration site conditions | | Pyrexia |
| Investigations | | Alanine aminotransferase increased, Aspartate aminotransferase increased, Aspergillus test positive |
\*\\* Based on 29 patients who have undergone myeloablative conditioning by busulfan in the\* integrated \*data set.\*
\*\*Description of selected adverse reactions\*\*
\*Presence of Anti ARSA Antibodies\*
Five out of 35 patients tested positive for anti-ARSA antibodies (AAA) at various post-treatment time points and had the event “Antibody test positive / Presence of antibodies against arylsulfatase A” reported by the Investigator.
Antibody titres were generally low and resolved either spontaneously or after a short course of rituximab.
In all patients with positive AAA test results, no negative effects were observed in the post-treatment ARSA activity of peripheral blood or bone marrow cellular subpopulations nor in the ARSA activity within the cerebrospinal fluid.
Patients treated with Libmeldy should be regularly monitored for AAA (see section 4.4).
\*Peripheral blood mobilisation and apheresis\*
During the clinical studies, haematopoietic stem cell collection was performed either through bone marrow (BM) harvest or peripheral blood mobilisation. The safety profile of BM harvest and mobilisation/apheresis were consistent with the known safety and tolerability of both procedures and the SmPC of mobilisation agents (G-CSF and plerixafor).
No serious adverse events were reported as potentially attributable to BM harvest within the range of BM volumes harvested (median volume was 35.5 mL/kg; range: 15.1-56.4 mL/kg). In the Integrated Safety Set (n=29), one patient experienced bone pain, which was qualified as a grade 2 adverse event and deemed related to the BM harvest procedure, but unrelated to the volume harvested.
No serious adverse events were reported as potentially attributable to mobilisation and apheresis and none of the patients who underwent mobilisation experienced any adverse events in the pre-treatment phase which could have been attributed to the mobilising agents.
\*\*Reporting of suspected adverse reactions\*\*
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.4.9 Overdose
No data from clinical studies are available regarding overdose of Libmeldy.
- Instruction Pharmacology
- 5.1 Pharmacodynamic properties
Pharmacotherapeutic group: Other haematological agents, ATC code: A16AB21.
\*\*Mechanism of action\*\*
Libmeldy is an \*ex vivo\* genetically modified autologous CD34+ haematopoietic stem and progenitor cell (HSPC) gene therapy. Autologous CD34+ HSPCs are collected from mobilised peripheral blood (mPB) and transduced with a lentiviral vector (ARSA LVV), which inserts one or more copies of the human ARSA complementary deoxyribonucleic acid (cDNA) into the cell's genome, so that genetically modified cells become capable of expressing the functional ARSA enzyme. When administered to the patient following the administration of a myeloablative conditioning regimen, the genetically modified cells engraft and are able to repopulate the haematopoietic compartment. A subpopulation of the infused HSPCs and/or their myeloid progeny is able to migrate across the blood brain barrier to the brain and engraft as central nervous system (CNS) resident microglia and perivascular CNS macrophages as well as endoneural macrophages in the peripheral nervous system (PNS). These genetically modified cells can produce and secrete the functional ARSA enzyme, which can be taken up by surrounding cells, a process known as cross-correction, and used to break down, or prevent the build-up, of harmful sulfatides.
Following successful and stable engraftment in the patient, the effects of the product are expected to be persistent.
\*\*Pharmacodynamic effects\*\*
Durable and stable peripheral engraftment of genetically modified cells was observed from 1-month post Libmeldy administration in all evaluable patients. A persistent vector copy number (VCN) was also observed in CD34+ cells isolated from the bone marrow throughout the follow-up period. These biological findings demonstrate a sustained multilineage engraftment of gene-corrected cells, which is essential for supporting the long-term production of ARSA and resulting long-term clinical benefit.
At Year 1 post-treatment, the proportion of BM-derived colonies harbouring the LVV genome (%LV+) in the overall treated population was 54.8% (range: 20.0% to 100%, [N=23]). The proportion of BM-derived colonies harbouring the LVV genome (%LV+) at Year 5 was 45.0% (range: 18.8% to 90.6% [n=6, 4 Late infantile (LI) and 2 Early Juvenile (EJ)]), indicative of stable engraftment over time in the treated population.
Reconstitution of ARSA activity in the haematopoietic system was observed in all MLD patients treated, with a progressive reconstitution of ARSA levels in Peripheral Blood Mononuclear Cells (PBMCs) which reached values within the normal reference range by 3 months post-treatment and remained stable within or above the normal range throughout the duration of the follow-up (see Figure 1).
\*\*Figure 1 ARSA activity in PBMCs over time (geometric mean and 95% CIs), by disease subtype (integrated efficacy set; N=29)\*\*
Note: Values < LLQ are imputed at LLQ. LLQ is 25.79 nmol/mg/h. GMs and 95% CIs are presented where there are at least 3 patients with non-missing data. ARSA: arylsulfatase A; CI: confidence interval; GM: geometric mean; LLQ: lower limit of quantification; PBMCs: peripheral blood mononuclear cells.
ARSA activity was also measured in cerebrospinal fluid (CSF) as a surrogate compartment of metabolic correction in the brain. The ARSA activity in CSF went from undetectable at Baseline to detectable in all evaluable patients by Month 6 post-treatment and reached reference range levels at Year 1 post-treatment. Thereafter, central reconstitution of ARSA enzymatic activity remained stable within the reference range.
\*\*Clinical efficacy\*\*
Clinical efficacy was based on the integrated analysis of results from 29 early-onset MLD patients treated with Libmeldy prepared as a fresh (non-cryopreserved) formulation. These results were generated in twenty (20) patients treated in the Registrational Study (Study 201222 - an open-label, non-randomized, single-arm safety and efficacy clinical trial) with a median duration of post-treatment follow-up of 4.0 years (range: 0.6 to 7.5 years) and nine (9) patients treated in the context of 3 expanded access programs with a median follow-up of 1.5 years (range: 0.99 years to 2.72 years).
In addition, initial results from 9 patients treated in a further study with the commercial (cryopreserved) formulation of Libmeldy (Study 205756) are summarised below.
The MLD disease spectrum can present in a variety of clinical forms, primarily based on the age of onset of the first symptoms of the disease. Pre-symptomatic Late Infantile (LI) or Early Juvenile (EJ) MLD patients and early symptomatic EJ MLD patients with biallelic mutations in the ARSA gene leading to a reduction of the ARSA enzymatic activity were included in the clinical development of Libmeldy. 'Biallelic mutations leading to a reduction of the ARSA enzymatic activity' refers to mutations leading to partial or total disruption of the ARSA enzymatic activity and resulting in accumulation of sulfatides. These biallelic mutations exclude common neutral mutations described in association with ARSA pseudo-deficiency alleles.
\*Patients and disease characteristics\*
The MLD forms (variants) were defined by the presence of the following criteria during the clinical development:
• Late infantile (LI): age at onset of symptoms in the older sibling(s) ≤30 months and/or 2 null (0) mutant ARSA alleles and/or peripheral neuropathy at electroneurography (ENG) study.
• Early juvenile (EJ): age at onset of symptoms (in the patient or in the older sibling) between 30 months and before 7 years, and/or 1 null (0) and 1 residual (R) mutant ARSA allele(s) and/or peripheral neuropathy at ENG study.
In the above definition, null (0) or residual (R) alleles refer to either known or novel mutations.
The symptomatic status of the patients was defined as follows:
• Pre-symptomatic: at time of inclusion into the clinical studies, LI or EJ patients were without neurological impairment (disease-related symptoms), with or without signs of the disease revealed by instrumental evaluations i.e. electroneurographic study (ENG) and brain magnetic resonance imaging (MRI).
Based on an analysis of the baseline characteristics of pre-symptomatic LI and EJ patients treated during the clinical development program, the definition of pre-symptomatic status was further refined to maximise the treatment benefit.
Taking the results of this analysis into account, treatment with Libmeldy of a pre-symptomatic patient should be considered:
- For a patient with the LI form of the disease, in the absence of a delay in achievement of independent standing, or a delay in achievement of independent walking, associated with abnormal signs at neurological evaluation.
- For a patient with the EJ form of the disease, in the absence of neurological signs or symptoms of the disease resulting in cognitive, motor, or behavioural functional impairment or regression (substantiated by neurological examination, gross motor function evaluation and/or age appropriate neuropsychological tests).
- Early symptomatic: at time of inclusion into the clinical studies, early symptomatic EJ patients met the following 2 criteria: intelligence quotient (IQ) ≥70 and the ability to walk independently for ≥ 10 steps.
Based on the analysis of clinically relevant benefits on the motor and cognitive functions, efficacy was only demonstrated in patients treated before the onset of cognitive deterioration at a time when they were still able to walk independently.
Taking these results into consideration, treatment with Libmeldy of a patient with an early-symptomatic EJ form of the disease should be considered:
- If this patient is able to walk independently, which means that the patient's GMFC-MLD score is ≤ 1, and
- If the patient's cognitive function has not started declining, which means that the patient's IQ is ≥ 85.
At time of inclusion in the clinical studies, out of the 29 early-onset MLD patients, 20 were pre-symptomatic and 9 were early symptomatic, 16 had a diagnosis of LI MLD and 13 had a diagnosis of EJ MLD. All LI study patients and some EJ patients were identified after an older sibling had developed symptoms and received an MLD diagnosis, prompting testing in other family members.
\*\*Table 3\*\* \*\*Summary of demographic characteristics by symptomatic status at time of gene therapy and by disease subtype (Integrated efficacy set)\*\*
| | | | | |
| --- | --- | --- | --- | --- |
| | \*\*Pre-symptomatic patients\*\* | | \*\*Early symptomatic patients\*\* | |
| \*\*Late Infantile subgroup (N=15)\*\* | \*\*Early Juvenile subgroup (N=5)\*\* | \*\*Late Infantile subgroup (N=1)\*\* | \*\*Early Juvenile subgroup (N=8)\*\* |
| \*\*Sex, n (%)\*\* | | | | |
| Female | 5 (33) | 2 (40) | 1 (100) | 5 (63) |
| Male | 10 (67) | 3 (60) | 0 | 3 (38) |
| \*\*Age at GT, in months\*\* | | | | |
| Median | 13.1 | 48.9 | 23.3 | 77.9 |
| Min | 7.6 | 11.4 | 23.3 | 38.8 |
| Max | 17.8 | 66.8 | 23.3 | 139.9 |
\*Mobilisation and apheresis\*
During the clinical development, all (ten) patients for whom the decision was made to use mPB as the source material – and not to conduct a BM harvest - were administered G-CSF (10-12.5 μg/kg/day) to mobilise CD34+ cells prior to the apheresis procedure. Starting from day 3 of G-CSF administration, an additional mobilising agent, plerixafor, was given once daily (0.24 mg/kg, subcutaneous) if clinically indicated depending on the white blood cells and CD34+ cell count in the patient's peripheral blood. Apheresis was performed as soon as the CD34+ cell count reached an adequate level, according to standard procedures.
If the target number of collected CD34+ cells to manufacture Libmeldy and to provide the back-up transplant were not reached with a single apheresis, a second procedure was performed. For all patients, the minimum number of CD34+ cells to manufacture Libmeldy (8 x 106 CD34+ cells/kg) was collected with 1 cycle of mobilisation and 1 or 2 apheresis.
\*Pre-treatment conditioning\*
All patients received systemic conditioning with busulfan prior to treatment with Libmeldy.
Thirteen patients (45%) were treated with a sub-myeloablative conditioning (SMAC) regimen, defined as a target cumulative AUC of 67,200 μg\\*h/L. Sixteen patients (55%) were treated with a myeloablative (MAC) conditioning regimen, defined as a target cumulative AUC of 85,000 μg\\*h/L.
For the SMAC conditioning regimen, patients received a total of 14 doses of busulfan (according to patient's weight), as a 2-hour IV infusion administered every 6 hours from Day -4 to Day -1. Busulfan plasma levels were monitored by serial pharmacokinetic sampling and adjusted using a target dose AUC of 4800 μg\\*h/L (range: 4200 to 5600 μg\\*h/L), which corresponds to an expected total cumulative AUC of 67,200 µg\\*h/L (range 58,800 to 78,400 μg\\*h/L). The average, cumulative AUC in patients who received a SMAC regimen was higher than expected but remained within the target range (geometric mean 71,923.53 [95% CI: 68,751.04, 75,242.41]).
For the MAC conditioning regimen, patients received body-surface area-based dosing of busulfan according to the patients age (80 mg/m2/dose if ≤ 1year; 120 mg/m2/dose if >1 year) for a total of 4 doses, administered as a 3 hour IV infusion every 20 to 24 hours from Day -4 to Day -1. Busulfan plasma levels were monitored by serial pharmacokinetic sampling and adjusted using a target total cumulative AUC of 85,000 µg\\*h/L (range: 76,500 to 93,500 µg\\*h/L).
Subgroup analyses by conditioning regimen i.e. comparison of the subgroups of patients who received the MAC vs. the SMAC regimen, didn't show noticeable differences in the level of transduced cell engraftment nor in ARSA enzyme activity (in total PBMCs and BM-derived mononuclear cells). Moreover, the safety profiles of both regimens were shown to be comparable.
Therefore, the decision to use the MAC or SMAC regimen for pre-treatment conditioning is at the discretion of the treating physician, taking into consideration the patient's clinical characteristics such as, but not limited to, age, hepatic function, prematurity and thrombophilia.
During clinical development, prophylaxis for veno-occlusive disease (VOD) and related endothelial injury complications was required per institutional practice with ursodeoxycholic acid or defibrotide.
\*Libmeldy administration\*
All patients (N=29) were administered the medicinal product with a mean (min, max) cell dose of 10.81 x 106 (4.2, 25.9) CD34+ cells/kg as an intravenous infusion.
\*Integrated efficacy results (N=29)\*
The co-primary efficacy endpoints were:
• Gross Motor Function Measure (GMFM): An improvement of >10% of the total GMFM score in treated patients, when compared to the GMFM scores in the age-matched, untreated historical control MLD population (i.e., TIGET natural history [NHx] Study), evaluated at Year 2 after treatment (see Table 4), and
• ARSA activity: A significant (≥2 SD) increase in residual ARSA activity as compared to pre-treatment values, measured in peripheral blood mononuclear cells (PBMC) at Year 2 after treatment (see Pharmacodynamic Effects, Figure 1 and Table 5).
Early-onset MLD patients treated before the onset of overt symptoms showed normal motor development, stabilisation, or delay in the rate of progression of motor dysfunction as measured by GMFM total score (%) (see Table 4).
Using an ANCOVA model adjusted for age at GMFM assessment and treatment, the mean difference between treated pre-symptomatic LI patients and age matched untreated LI patients from the NHx study was 71.0% at Year 2 and 79.8% at Year 3. Similarly, the mean difference between treated pre-symptomatic EJ patients and aged matched untreated EJ patients was 52.4% at Year 2 and 74.9% at Year 3. These treatment differences were statistically significant (p≤0.008) in favour of Libmeldy.
Although not statistically significant, a clear difference in GMFM total score was also noted between treated early symptomatic EJ patients and aged matched untreated EJ patients (28.7% at Year 2; p=0.350 and 43.9% at Year 3; p=0.054).
\*\*Table 4 GMFM total score (%) at Year 2 and Year 3 in pre-symptomatic and early-symptomatic patients (late infantile and early juvenile subgroups) with comparison to age-matched natural history data (integrated efficacy set).\*\*
| | | | | |
| --- | --- | --- | --- | --- |
| | | \*\*Adjusted mean GMFM total score\*\* | | \*\*Mean treatment difference in GMFM total score between treated patients and age-matched untreated natural history patients\*\* |
| \*\*Treated patients\*\* | \*\*Untreated natural history patients\*\* |
| \*\*Pre-symptomatic patients\*\* | \*\*Late infantile\*\* | | | |
| \*\*Year 2\\*\*\* | 79.5% (n=10) | 8.4% (n=8) | 71.0% (95% CI: 60.4 – 81.7); p<0.001 |
| \*\*Year 3\*\* | 82.6% (n=9) | 2.8% (n=9) | 79.8% (95% CI: 66.2 – 93.3) p<0.001 |
| \*\*Early juvenile\*\* | | | |
| \*\*Year 2\\*\*\* | 96.7% (n=4) | 44.3% (n=8) | 52.4% (95% CI: 25.1 – 79.6); p=0.008 |
| \*\*Year 3\*\* | 93.2% (n=4) | 18.2% (n=9) | 74.9% (95% CI: 50.8 – 99.1); p<0.001 |
| \*\*Early Symptomatic patients\*\* | \*\*Early juvenile\*\* | | | |
| \*\*Year 2\\*\*\* | 60.7% (n=6) | 31.9% (n=10) | 28.7% (95% CI: -14.1 – 71.5); p=0.350 |
| \*\*Year 3\*\* | 59.8% (n=6) | 15.9% (n=10) | 43.9% (95% CI: 9.2 – 78.5); p=0.054 |
\\* The Gross Motor Function Measure at two years after treatment was a co-primary endpoint of the registrational clinical study. Note: Analysis of covariance adjusting for treatment and age. P-values are from a two-sided 5% hypothesis test with null hypothesis of 10% difference. CI: confidence interval; EJ: early juvenile; GMFM: gross motor function measurement; LI: late infantile; MLD: metachromatic leukodystrophy.
Deterioration of gross motor function was assessed from disease onset in EJ patients who were early-symptomatic at the time of gene therapy. By four years post disease onset, the estimated proportion of patients who survived and maintained locomotion and ability to sit without support (GMFC-MLD level 5 or higher) was 62.5% in the treated group compared to 26.3% in the untreated group, representing a delay in disease progression following treatment with Libmeldy.
A statistically significant increase in ARSA activity in PBMCs was also observed at Year 2 post-treatment compared to pre-treatment baseline in both pre-symptomatic patients (20.0-fold increase; p<0.001) and early symptomatic patients (4.2-fold increase; p=0.004) (See Table 5).
\*\*Table 5 ARSA activity measured in PBMCs (geometric mean) at Baseline and Year 2 after treatment in pre-symptomatic and early-symptomatic patients (integrated efficacy set).\*\*
| | | | |
| --- | --- | --- | --- |
| | \*\*Geometric mean (%CVb)\*\* \*\*ARSA Activity in PBMCs\*\* | | \*\*Fold Increase from Baseline to Year 2 \\*\*\* |
| \*\*Baseline\*\* | \*\*Year 2\*\* |
| \*\*Pre-symptomatic\*\* | 26.923 (16.72) (n=19) | 339.736 (270.85) (n=14) | 20.0 (95% CI: 9.0, 44.0) p<0.001 |
| \*\*Early-symptomatic\*\* | 26.025 (2.72) (n=9) | 134.056 (55.94) (n=6) | 4.2 (95% CI: 1.6, 11.2) p=0.004 |
\\* Ratio in adjusted means from a mixed model repeated measures of data on the log scale, adjusting for visit, baseline, baseline by visit interaction, disease subtype and disease subtype by visit interaction
A secondary efficacy endpoint of the integrated efficacy analysis was measurement of IQ above 55 post-treatment with Libmeldy, the threshold for moderate mental retardation (DSM-IV), using neuropsychological tests. Intelligence Quotient/Development Quotient (IQ/DQ) measures, i.e. cognitive and language abilities, complement results from the GMFM and provide further evidence that the high levels of engraftment and enzymatic reconstitution translate into relevant treatment effects on key symptomatic domains in MLD patients.
In the LI subgroup (all pre-symptomatic at time of treatment except one), 12 out of 15 assessed patients had a fairly constant IQ/DQ, within the normal range (IQ/DQ score of 100 +/- SD of 15) throughout follow-up. All but 2 of these patients (one pre-symptomatic, one early-symptomatic) remained above the threshold of severe mental disability (IQ/DQ >55) at chronological ages at which all 14 untreated NHx patients with neuropsychological assessments showed evidence of severe cognitive impairment (i.e. IQ/DQ below 55 and close to 0).
Of the 10 surviving EJ patients, all 4 pre-symptomatic patients and 4 out of 6 early-symptomatic patients showed normal IQ/DQ throughout follow-up. In contrast, 11 out of 12 NHx patients with neuropsychological assessments showed evidence of severe cognitive impairment during follow-up.
At the time of the integrated data analysis, i.e. at a median follow-up time of 3.035 years post-treatment (range 0.99 to 7.51), none of the 16 patients in the treated LI subgroup, all pre-symptomatic at time of treatment except one, had died (100% overall survival). Four pre-symptomatic LI patients were alive 6 or more years after treatment and 2 pre-symptomatic LI patients were alive 7 or more years after treatment. In comparison, 12 out of 19 (63.2%) untreated LI patients in the NHx study had died at the time of the analysis.
Comparable overall survival was observed in the treated and untreated EJ groups with a median follow-up time of 3.49 years post-treatment (range 0.64 to 6.55). One out of 5 (20%) EJ patients treated at pre-symptomatic stage died, due to cerebral ischemic infarction, not deemed related to Libmeldy. There were 2 deaths among the 8 (25.0%) EJ patients treated at early-symptomatic stage, both due to disease progression, and also not considered to be related to Libmeldy treatment. Similarly, 3 of the 12 (25%) untreated EJ patients in the NHx study had died at the time of the analysis.
A sensitivity analysis conducted to identify clinical factors, which could have influenced the level of treatment benefit with Libmeldy and optimize the recommended use of the treatment, identified 4 treatment failures:
- One LI patients experienced onset of disease-related symptoms between screening and administration of Libmeldy and was considered symptomatic at the time of treatment. The progression of this patient post-treatment was comparable to untreated NHx patients in both cognitive function and motor development.
- Three early symptomatic EJ patients treated with Libmeldy showed deterioration in both motor and cognitive functions comparable to that observed in untreated NHx patients and progression of the disease led to death in two of them. Two out of the three patients showed IQ<85 (82 and 58) at the time of treatment. Two out of the three patients showed deterioration between screening and baseline (onset of conditioning regimen) assessments.
\*Study 205756 (cryopreserved commercial formulation)\*
Study 205756 is an open-label, single-arm study to evaluate the cryopreserved (commercial) formulation of Libmeldy in the treatment of pre-symptomatic LI and pre-symptomatic and early symptomatic EJ MLD patients. The cell dose range used in the first 9 patients in Study 205756 (10.45-30.0 x 106 CD34+ cells/kg) is close to the range used in patients treated with the fresh (investigational) formulation of the medicinal product (4.2-25.9 x 106 CD34+ cells/kg).
At the time of data cut, 6 patients (3LIs, 3EJs), all pre-symptomatic at the time of treatment, have been treated, with a median follow-up post-treatment of 0.87 year (range: 0.0 to 1.47 years). Preliminary efficacy data show levels of engraftment, Vector Copy Number, ARSA activity in PBMCs and CSF at different timepoints post-gene therapy within the range observed in the integrated data analysis of the patients treated with the fresh formulation of Libmeldy.
Preliminary safety data indicate that Libmeldy was well tolerated. The safety profile observed in this study with the cryopreserved formulation is consistent with the profile established in patients treated with the fresh formulation in terms of nature, time of onset and frequency of reported adverse events.
\*Paediatric population\*
Libmeldy has been studied in infants and children with an age range between 7.6 months and 11.6 years.
The European Medicines Agency has deferred the obligation to submit the results of studies with Libmeldy in the late juvenile subset of the paediatric population with metachromatic leukodystrophy (i.e. MLD patients aged between 7 and less than 17 years at time of disease onset) (see section 4.2 for information on paediatric use).5.2 Pharmacokinetic properties
Libmeldy is a gene therapy medicinal product consisting of autologous cells that have been genetically modified \*ex vivo\*. The nature of Libmeldy is such that conventional studies on pharmacokinetics, absorption, metabolism, and elimination are not applicable. The biodistribution of Libmeldy was nonetheless studied and distribution to haematopoietic tissues and disease target organs (including the brain) was demonstrated.5.3 Preclinical safety data
Due to the nature of Libmeldy, a standard toxicological assessment was not applicable and conventional mutagenicity, carcinogenicity and reproductive and developmental toxicity studies have not been conducted.
The pharmacology, toxicology and genotoxicity of Libmeldy were evaluated \*in vitro\* and in \*vivo\*. Integration site analysis (ISA) of mouse Lin- bone marrow cells and human CD34+ cells transduced with ARSA LVV was conducted pre- and post-transplantation into mice and showed no enrichment for insertion in or near cancer-related genes, or clonal dominance. A prototype lentiviral vector related to ARSA LVV did not induce \*in vitro\* transformation and sustained growth of transduced wild type mouse Lin- bone marrow cells due to insertional transformation. Lin- bone marrow cells from Cdkn2a-/- mice, a strain prone to cancer triggered by gamma-retroviral insertional mutagenesis, transduced with the same prototype lentiviral vector did not show genotoxic potential when transplanted into wild type mice.
Toxicity and oncogenesis (tumorigenicity) studies were performed in the mouse model of MLD. No evidence of toxicity due to ARSA overexpression and no abnormal or malignant growth of transplanted cells or haematopoietic tumours related to the integration of ARSA LVV were observed. ARSA overexpression in human HSPCs and in ARSA Tg mice did not impair the activation of other sulfatases dependent on the sulfatase activator SUMF-1, did not affect the proliferation and differentiation capacities of transduced cells and did not induce toxicity or functional impairment in ARSA Tg mice.
Additional studies with human CD34+ cells transduced with ARSA LVV administered to immunodeficient, myeloablated mice demonstrated no toxicity, no vector mobilisation and bystander transduction of male gonads.
Molecular monitoring did not detect replication competent lentivirus (RCL).
- Instruction Pharmaceutical Particulars
- 6.1 List of excipients
Dimethylsulfoxide
Sodium chloride
Human albumin6.2 Incompatibilities
In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.6.3 Shelf life
6 months.
Once thawed: maximum 2 hours at room temperature (20 °C-25 °C).6.4 Special precautions for storage
Keep the infusion bag(s) in the metal cassette(s).
Libmeldy must be stored in the vapour phase of liquid nitrogen (< -130 °C) and must remain frozen until the patient is ready for treatment to ensure viable cells are available for patient administration. Thawed medicinal product should not be refrozen.
For storage conditions after thawing of the medicinal product, see section 6.3.6.5 Nature and contents of container
50 mL ethylene vinyl acetate (EVA) infusion bag(s) with two available spike ports, packed in an EVA overwrap bag placed inside a metal cassette.
Libmeldy is shipped from the manufacturing facility to the treatment centre storage facility in a cryoshipper, which may contain multiple metal cassettes intended for a single patient. Each metal cassette contains one infusion bag of Libmeldy.6.6 Special precautions for disposal and other handling
\*\*Precautions to be taken before handling or administering the medicinal product\*\*
• This medicinal product contains human blood cells. Healthcare professionals handling Libmeldy must take appropriate precautions (wearing gloves, protective clothing and eye protection) to avoid potential transmission of infectious diseases.
• Libmeldy must remain at <-130 °C at all times, until the content of the bag is thawed for infusion.
\*\*Definition of the dose to be administered\*\*
• Considering the posology information provided in section 4.2, the dose to be infused and number of infusion bags to be used should be defined based on the total number of CD34+ cells supplied indicated on the Lot Information Sheet (i.e. the 'supplied dose', calculated based on patient's weight at time of cell harvest). The dose of Libmeldy to be administered should also take into account the patient's weight at the time of treatment, and the fact that any bag used should be administered in its entirety.
• Careful consideration must be given to the volume of infusion in relation to age and weight of the patient. When the dose of Libmeldy to be infused represents more than one bag, it should be ensured prior to infusion that the volume of medicinal product to be infused is compatible with the recommended limit of DMSO, i.e. the total volume of DMSO administered should remain <1% of the patient's estimated plasma volume. Therefore, the maximum volume of Libmeldy to be administered should remain < 20% of the patient's estimated plasma volume.
• The following graph is provided as a reference in order to determine the maximum volume of Libmeldy which can be infused to a patient based on their estimated plasma volume.
\*\*Figure 2 Guidance on DMSO safety limit: the maximum volume of Libmeldy to be administered should remain < 20% of the patient's estimated plasma volume.\*\*
\*\*Preparation\*\* \*\*prior to administration\*\*
• A patient may have multiple infusion bags. Each infusion bag is provided inside an overwrap bag, which is contained in a metal cassette.
• The overwrapped infusion bag(s) must be kept inside the metal cassette(s) in the vapour phase of liquid nitrogen at < -130 °C until ready to thaw and infuse.
• Account for all infusion bags and confirm each infusion bag is within the expiry date using the accompanying Lot Information Sheet.
• Sterile sodium chloride 9 mg/mL (0.9%) solution for injection should be available to prime the tubing prior to infusion, and to flush the infusion bag and tubing after infusion.
\*\*Checking prior to thawing\*\*
• Do not remove the metal cassette from cryogenic storage or thaw Libmeldy until the patient is ready to be infused. The timing of thaw of the infusion bag(s) containing Libmeldy and of the infusion should be coordinated. Confirm the infusion time in advance and adjust the start time for thaw so that the treatment is available for infusion when the patient is ready.
• Open the metal cassette and inspect the overwrap bag and infusion bag for any breaches of integrity before thawing. If an infusion bag is compromised, follow the local guidelines for handling of waste of human-derived material and contact Orchard Therapeutics immediately.
• Prior to thawing Libmeldy, it must be verified that the patient identity matches the unique patient information reported on the packaging labels and on the accompanying Lot Information Sheet. Libmeldy is intended solely for autologous use. Do not thaw or infuse Libmeldy if the information on the patient-specific label on the infusion bag does not match the intended patient.
\*\*Thawing\*\*
• After careful removal from the metal cassette, thaw the infusion bag in its sealed overwrap bag at 37 °C in a controlled thawing device until there is no visible ice in the infusion bag.
• Once thawing is complete, the bag should be removed immediately from the thawing device.
• The overwrap bag should be carefully opened to remove the infusion bag which should be kept at room temperature (20 °C-25 °C) until infusion.
• Gently massage the infusion bag to resuspend the cells. The content of the infusion bag should be inspected for any remaining visible cellular aggregates. Small clumps of cellular material should disperse with gentle manual mixing. Do not shake the bag.
• The infusion bag should not be washed, spun down, sampled and/or resuspended in new media prior to infusion.
• Libmeldy should not be irradiated as irradiation could lead to inactivation of the product.
• If more than one infusion bag is provided for the patient treatment dose, the next bag should only be thawed after the content of the preceding bag has been fully infused.
\*\*Administration\*\*
• Libmeldy should be administered as an intravenous infusion via a central venous catheter, per the administration site's standard procedures for cell therapy products.
• The recommended administration set consists of a blood transfusion set equipped with a 200µm filter.
• Each bag should be infused by gravity within 2 hours of thaw, including any interruption during the infusion, to maintain maximum product viability.
• The maximum infusion rate is 5 mL/kg/h, and the content of each bag should be infused within approximately 30 minutes.
• When more than one bag of Libmeldy is needed, only one bag of product should be infused per hour.
• Patients not previously exposed to DMSO should be observed closely. Vital signs (blood pressure, heart rate, and oxygen saturation) and the occurrence of any symptom should be monitored for up to 3 hours following the infusion.
• At the end of the infusion, flush all Libmeldy remaining in the infusion bag and any associated tubing with sodium chloride 9 mg/mL (0.9%) solution for injection to ensure that as many cells as possible are infused into the patient. Careful consideration must be given to the volume of infusion in relation to the age and weight of the patient.
\*\*Measures to take in case of accidental exposure\*\*
• In case of accidental exposure local guidelines on handling of human-derived materials must be followed. Work surfaces and materials which have potentially been in contact with Libmeldy must be decontaminated with appropriate disinfectant.
\*\*Precautions to be taken for the disposal of the medicinal product\*\*
• Unused medicinal products and all material that have been in contact with Libmeldy (solid and liquid waste) should be handled and disposed of as potentially infectious waste in accordance with local guidelines on handling human-derived material.
- Instruction Content
- ## Pharmaceutical Form
Dispersion for infusion.
A clear to slightly cloudy, colourless to yellow or pink dispersion.
## Clinical Particulars
4.1 Therapeutic indications
Libmeldy is indicated for the treatment of metachromatic leukodystrophy (MLD) characterized by biallelic mutations in the arylsulfatase A (ARSA) gene leading to a reduction of the ARSA enzymatic activity:
- in children with late infantile or early juvenile forms, without clinical manifestations of the disease,
- in children with the early juvenile form, with early clinical manifestations of the disease, who still have the ability to walk independently and before the onset of cognitive decline (see section 5.1).4.2 Posology and method of administration
Libmeldy must be administered in a qualified treatment centre by a physician with experience in Haematopoietic Stem Cell Transplantation (HSCT) and trained for administration and management of patients treated with the medicinal product.
\*\*Posology\*\*
Libmeldy is intended for autologous use (see section 4.4) and should only be administered once.
The dose of Libmeldy must be determined based on the patient's body weight at the time of infusion.
Treatment consists of a single dose for infusion containing a dispersion of viable CD34+ cells in one or more infusion bags.
The minimum recommended dose of Libmeldy is 3 × 106 CD34+ cells/kg of body weight. In clinical studies, doses up to 30 × 106 CD34+ cells/kg have been administered.
The maximum volume of Libmeldy to be administered should remain < 20% of the patient's estimated plasma volume (see section 4.4 and section 6.6).
See the accompanying Lot Information Sheet (LIS) for additional information pertaining to dose.
\*Peripheral blood mobilisation and apheresis\*
The autologous CD34+ cells are isolated from mobilised peripheral blood (mPB). This is achieved by apheresis procedure(s) following peripheral blood mobilisation.
For manufacture of Libmeldy, the patient must be able to donate a minimum of 8-10 ×106 CD34+ cells/kg, considering that the optimal range is between 20-30 × 106 CD34+ cells/kg.
The minimum CD34+ cell quantity may be achieved using one or more cycles of apheresis.
If, after medicinal product manufacturing, the minimum dose of Libmeldy of 3 × 106 CD34+ cells/kg is not achieved, the patient may undergo a further mobilisation protocol with one or more cycles of apheresis, in order to obtain more cells for additional manufacture (see \*Mobilisation and apheresis\* in section 5.1).
A back-up collection of HSPC containing at least 2 x 106 CD34+ cells/kg is also required for use as rescue treatment should the quality of Libmeldy be compromised after initiation of myeloablative conditioning and before Libmeldy infusion, failure of primary engraftment, or prolonged bone marrow aplasia after treatment with Libmeldy (see section 4.4).
These cells must be collected from the patient and be cryopreserved according to institutional procedures prior to myeloablative conditioning. The back-up cells may be harvested either through mPB apheresis or bone marrow harvest.
\*Peripheral blood mobilisation\*
Patients are required to undergo HSPC mobilisation with Granulocyte colony-stimulating factor (G-CSF) with or without plerixafor followed by apheresis to obtain CD34+ stem cells for medicinal product manufacturing (see section 5.1 for a description of the mobilisation regimen used in clinical studies).
\*\*Pre-treatment conditioning\*\*
The treating physician should confirm that autologous HSPC gene therapy administration is clinically appropriate for the patient before myeloablative conditioning is initiated (see section 4.4).
A myeloablative conditioning is required before infusion of Libmeldy to promote efficient engraftment of the genetically modified autologous CD34+ cells (see section 5.1 for a description of the myeloablative regimen used in clinical studies).
Busulfan is the recommended conditioning medicinal product.
Myeloablative conditioning should not begin until the complete set of infusion bag(s) constituting the dose of Libmeldy has been received and stored at the qualified treatment centre, and the availability of the back-up collection is confirmed.
Concurrently with the conditioning regimen, and prior to treatment with Libmeldy, it is recommended that patients receive prophylaxis for veno-occlusive disease (VOD) and related endothelial injury complications i.e. transplant-associated thrombotic microangiopathy (TA-TMA) or atypical haemolytic uremic syndrome (aHUS), in line with local guidelines.
Depending on the myeloablative conditioning regimen administered, prophylaxis for seizures should also be considered. Phenytoin is not recommended as it may increase busulfan clearance.
Prophylactic and empiric use of anti-infectives (bacterial, fungal, viral) should be considered for the prevention and management of infections especially during the neutropenic period following conditioning. Routine monitoring of most common viruses subject to re-activation is recommended as per local guidelines. Infection control measures and isolation procedures should be employed during the hospitalization according to local standards.
\*\*Pre-medication\*\*
It is recommended that pre-medication with intravenous chlorpheniramine (0.25 mg/kg, max. dose 10 mg), or equivalent medicinal products, be administered 15-30 minutes before the infusion of Libmeldy to reduce the possibility of an infusion reaction.
\*\*Special populations\*\*
\*Elderly\*
Libmeldy has not been studied in patients >65 years of age.
\*Renal impairment\*
Libmeldy has not been studied in patients with renal impairment. Patients should be assessed for renal impairment to ensure autologous HSPC gene therapy administration is appropriate. No dose adjustment is required.
\*Hepatic impairment\*
Libmeldy has not been studied in patients with hepatic impairment. Patients should be assessed for hepatic impairment to ensure autologous HSPC gene therapy administration is appropriate. No dose adjustment is required.
\*Paediatric population\*
The safety and efficacy of Libmeldy have not yet been established in patients with the late juvenile form of the disease (i.e. with a typical onset after 7 years of age). No data are available.
\*\*Method of administration\*\*
Libmeldy is for intravenous infusion only.
\*Precautions to be taken before handling or administering the medicinal product\*
This medicinal product contains genetically modified human cells. Healthcare professionals should therefore take appropriate precautions (wearing gloves and glasses) to avoid potential transmission of infectious diseases when handling the product.
For instructions on preparation, accidental exposure and disposal of Libmeldy, see section 6.6.
\*Preparation for infusion\*
Before administration, it must be confirmed that the patient's identity matches the unique patient information on the Libmeldy infusion bag(s) and accompanying documentation. The total number of infusion bags to be administered must also be confirmed with the patient specific information on the Lot Information Sheet (LIS) (see section 4.4).
The timing of thaw and infusion of Libmeldy should be coordinated. The infusion start time should be confirmed in advance and adjusted for thaw so that Libmeldy is available for infusion when the patient is ready. To maintain product viability, as soon as thawing is complete, it is recommended that Libmeldy be administered immediately. Administration must be completed within 2 hours from the time of thawing.
\*Administration\*
Administer the product as an intravenous infusion via a central venous catheter. When more than one bag of Libmeldy is needed, only one bag of medicinal product should be infused per hour. Each bag should be infused at an infusion rate which does not exceed 5 mL/kg/h, within approximately 30 minutes. The recommended administration set consists of a blood transfusion set equipped with a 200µm filter (see section 6.6).
For detailed instructions on preparation, administration, accidental exposure and disposal of Libmeldy, see section 6.6.4.3 Contraindications
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Previous treatment with haematopoietic stem cells gene therapy.
Contraindications to the mobilisation and the myeloablative medicinal products must be considered.4.4 Special warnings and precautions for use
\*\*Traceability\*\*
The traceability requirements of cell-based advanced therapy medicinal products must apply. To ensure traceability, the name of the product, the batch number and the name of the treated patient must be kept for a period of 30 years after expiry date of the product.
\*\*Autologous use\*\*
Libmeldy is intended solely for autologous use and must not, under any circumstances be administered to other patients. Libmeldy must not be administered if the information on the product labels and Lot Information Sheet (LIS) do not match the patient's identity.
\*\*Rapidly progressive phase of the disease\*\*
Treatment with Libmeldy should be performed before the disease enters its rapidly progressive phase.
Eligibility to treatment with Libmeldy should initially be assessed by the treating physician via full neurological examination, motor function assessment and neurocognitive assessment, as appropriate for the patients' age.
Prior to the commencement of cellular harvest, the treating physician should ensure that the patient has not clinically deteriorated. Thereafter, prior to the commencement of conditioning, the treating physician should ensure that autologous HSPC gene therapy administration remains clinically appropriate for the patient, and that treatment with Libmeldy is still indicated.
\*\*Mobilisation and myeloablative conditioning medicinal products\*\*
Warnings and precautions of the mobilisation and myeloablative conditioning medicinal products must be considered.
\*\*Central venous catheter (CVC) complications including infections and thromboses\*\*
Infections related to the use of CVCs have been reported in clinical studies and there is a risk of thrombosis associated with the CVC. Patients should be closely monitored for potential infections and catheter-related events.
\*\*Transmission of an infectious agent\*\*
Although Libmeldy is tested for sterility and mycoplasma, a risk of transmission of infectious agents exists. Healthcare professionals administering Libmeldy should therefore monitor patients for signs and symptoms of infections after treatment and treat appropriately, if needed.
\*\*Interference with virology testing\*\*
Due to limited and short spans of identical genetic information between the lentiviral vector used to create Libmeldy and HIV, some HIV nucleic acid tests (NAT) may give a false positive result.
Patients who have received Libmeldy should not be screened for HIV infection using a PCR-based assay.
\*\*Blood, organ, tissue and cell donation\*\*
Patients treated with Libmeldy should not donate blood, organs, tissues and cells for transplantation. This information is provided in the Patient Alert Card which must be given to the patient after treatment.
\*\*Hypersensitivity and infusion-related reactions\*\*
Serious hypersensitivity reactions, including anaphylaxismay be due to dimethylsulfoxide (DMSO) in Libmeldy. Patients not previously exposed to DMSO should be observed closely. Vital signs (blood pressure, heart rate, and oxygen saturation) and the occurrence of any symptom should be monitored prior to the start of the infusion, approximately every ten minutes during the infusion and every hour, for 3 hours, after the infusion.
When more than one bag of Libmeldy is needed, it should be ensured prior to infusion that the volume of medicinal product to be infused is compatible with the recommended limit of DMSO, i.e. the total volume of DMSO administered should remain <1% of the patient's estimated plasma volume. The maximum volume of Libmeldy to be administered should therefore remain < 20% of the patient's estimated plasma volume (see section 6.6).
Also, when more than one bag of Libmeldy is needed, only one bag of medicinal product should be infused per hour.
\*\*Engraftment failure\*\*
In clinical studies, no patients failed to engraft bone marrow, as measured by neutrophil count in peripheral blood. Failure of neutrophil engraftment is a short-term but potentially important risk, defined as failure to reach an absolute neutrophil count (ANC) >500 cells/μL associated with no evidence of bone marrow recovery (i.e. hypocellular marrow) by day 60 after Libmeldy infusion. In case of engraftment failure, the non-transduced back-up stem cells should be infused according to local standards (see section 4.2).
\*\*Prolonged cytopenia\*\*
Patients may exhibit severe cytopenias, including severe neutropenia [defined as Absolute Neutrophil Count (ANC) <500 cells/μL] and prolonged thrombocytopenia, for several weeks following myeloablative conditioning and Libmeldy infusion. In clinical studies, haematological recovery after conditioning with busulfan was typically seen four to five weeks from the day of infusion of Libmeldy. In the clinical study with the cryopreserved (commercial) formulation, neutrophil engraftment occurred after a median (min, max) of 36.5 (31-40) days after gene-therapy. Patients should, therefore, be monitored for signs and symptoms of cytopenia for at least 6 weeks after infusion.
Red blood cells should be monitored according to medical judgment until engraftment of these cells and recovery are achieved. Supportive transfusion of red cells and platelets should be given according to medical judgement and institutional practice. Blood cell count determination and other appropriate testing should be promptly considered whenever clinical symptoms suggestive of anaemia arise.
If cytopenia persists beyond six to seven weeks, despite the use of granulocyte mobilising medicinal products, the non-transduced back up stem cells should be infused. If cytopenia persists despite infusion of non-transduced back-up stem cells, alternative treatments should be considered.
\*\*Delayed platelet engraftment\*\*
Platelet engraftment is defined as the first of 3 consecutive days with platelet values ≥ 20 x 109/L obtained on different days after Libmeldy infusion, with no platelet transfusion administered for 7 days immediately preceding and during the evaluation period (up to 60 days post gene therapy).
During the clinical development, 4/35 patients (11.4%) reported delayed platelet engraftment (median: 73.5 days, range 65-109 days) which was not correlated with an increased incidence of bleeding. As part of the standard of care/prophylaxis, all patients in the integrated safety set (N=29) received transfusion support with platelets. Platelets counts should be monitored according to medical judgment until engraftment of these cells and recovery is achieved. Supportive transfusion of platelets should be given according to medical judgement and institutional practice.
\*\*Metabolic acidosis\*\*
Prior to a treatment with Libmeldy, the presence of renal tubular acidosis should be evaluated alongside risks of the conditioning medicinal product and risks of the gene therapy procedure, which may contribute to the development of metabolic acidosis. Acid-base status should be monitored throughout conditioning and until the patient is no longer under metabolic stress. The treating physician should consider sodium bicarbonate replacement alongside any other required treatment and should aim to correct any concurrent adverse reaction(s) that might contribute to metabolic acidosis.
\*\*Thyroid monitoring\*\*
Transient increases in thyroid stimulating hormone (TSH), free T4 (FT4; thyroxine) and free T3 (FT3; tri-iodothyronine) were observed in some patients during clinical studies. Considering that thyroid disorders could potentially be masked by critical illness or induced by concomitant medication, patients should be assessed for thyroid function and structure prior to treatment with Libmeldy. Thyroid function and structure should also be monitored in the short term after treatment, and as necessary thereafter.
\*\*Risk of insertional oncogenesis\*\*
There is a theoretical risk of leukaemia or lymphoma after treatment with Libmeldy. In the event that leukaemia or lymphoma is detected in any patient who received Libmeldy, blood samples should be collected for integration site analysis.
\*\*Anti-ARSA antibodies\*\*
During clinical development, anti-ARSA antibodies (AAA) were reported in 5 patients. Titers were generally low and resolved spontaneously or after treatment with rituximab (see section 4.8). No impacts on the clinical efficacy or safety outcomes were observed.
Monitoring of AAA is recommended prior to treatment, between 1 and 2 months after gene therapy, and then at 6 months, 1 year, 3 years, 5 years, 7 years, 9 years, 12 years, 15 years post treatment.
In a case of disease onset or significant disease progression, additional AAA monitoring is recommended.
\*\*Serological testing\*\*
Libmeldy has not been studied in patients with HIV-1, HIV-2, HTLV-1, HTLV-2, HBV, HCV or mycoplasma infection.
All patients should be tested for HIV-1/2, HTLV-1/2, HBV, HCV and mycoplasma prior to mobilisation to ensure acceptance of the cellular source material for Libmeldy manufacturing.
\*\*Anti-retroviral use\*\*
Patients should not take anti-retroviral medicinal products from at least one month prior to mobilisation until at least 7 days after Libmeldy infusion (see section 4.5). If a patient requires anti-retrovirals following exposure to HIV/HTLV, initiation of Libmeldy treatment should be delayed until an HIV/HTLV western blot and viral load assay have been performed at 6 months post-exposure.
\*\*After Libmeldy administration\*\*
After the infusion, standard procedures for patient management after HSPC \*\*transplantation\*\* should be followed.
Immunoglobulin G should be maintained above 5g/L to prevent potential late \*\*infections\*\* (occurring later than 100 days post therapy) associated with severe hypogammaglobinaemia, resulting from apheresis and conditioning.
Any blood products required within the first 3 months after Libmeldy infusion should be irradiated.
\*\*Long-term follow-up\*\*
Patients are expected to be enrolled in a long-term follow-up scheme in order to better understand the long-term safety and efficacy of Libmeldy.
\*\*Sodium content\*\*
This medicinal product contains 35 – 560 mg sodium per dose, which is equivalent to 2 to 28% of the WHO recommended maximum daily intake of 2 g sodium for an adult.4.5 Interaction with other medicinal products and other forms of interaction
No interaction studies have been performed.
The nature of Libmeldy is such that no pharmacokinetic interactions are expected with other medicinal products.
Patients should not take anti-retroviral medicinal products from at least one month \*\*prior\*\* to mobilisation until at least 7 days after Libmeldy infusion (see section 4.4).
\*\*Live vaccines\*\*
The safety of immunisation with live viral vaccines during or following treatment with Libmeldy has not been studied. As a precautionary measure, vaccination with live vaccines is not recommended for at least 6 weeks prior to the start of myeloablative conditioning, during Libmeldy treatment, and until haematological recovery following treatment.4.6 Fertility, pregnancy and lactation
As Libmeldy is not intended for use in adults, human data on use during pregnancy or lactation and animal reproduction studies are not available.
With regard to fertility, consult the SmPC of the myeloablative conditioning medicinal product. It should be noted that the treating physician should inform the patient's parents/carers about options for cryopreservation of spermatogonial stem cells or ovarian tissue.4.7 Effects on ability to drive and use machines
Not relevant.4.8 Undesirable effects
\*\*Summary of the safety profile\*\*
The safety of Libmeldy was evaluated in 35 patients with MLD.
The median duration of follow-up in the integrated safety data set, which included 29 patients treated with the fresh (investigational) formulation was 4.51 years (range: 0.64 to 8.85 years). Three patients died and a total of 26 patients remained in the follow-up phase.
The median duration of follow-up in the 6 patients treated with the cryopreserved (commercial) formulation was 0.87 years (range: 0.0 to 1.47 years). All of them remained in the follow-up phase (see section 5.1).
Given the small patient population, adverse reactions in the table below do not provide a complete perspective on the nature and frequency of these events.
Treatment with Libmeldy is preceded by medical interventions, namely haematopoietic stem cell collection peripheral blood mobilisation with G-CSF with or without plerixafor followed by apheresis, and myeloablative conditioning (preferably using busulfan), which carry their own risks. When assessing the safety of a treatment with Libmeldy, the safety profile and product information of the medicinal products used for peripheral blood mobilisation and myeloablative conditioning should be considered, in addition to the risks linked to the gene therapy.
\*\*Tabulated list of adverse reactions\*\*
Adverse reactions are listed by MedDRA body system organ class and by frequency. Frequencies are defined as: very common (≥1/10), and common (≥1/100 and <1/10).
\*\*Table 1 Adverse reactions attributed to Libmeldy\*\*
| | | |
| --- | --- | --- |
| \*\*System Organ Class\*\* | \*\*Very Common\*\* | \*\*Common\*\* |
| Immune system disorders | Antibody Test Positive (Anti ARSA Antibody) | |
\*\*Table 2 Adverse reactions potentially attributed to myeloablative conditioning\\*\*\*
| | | |
| --- | --- | --- |
| \*\*System Organ Class\*\* | \*\*Very Common\*\* | \*\*Common\*\* |
| Infections and infestations | | Cytomegalovirus viraemia, Pneumonia, Staphylococcal infection, Urinary tract infection, Viral infection |
| Blood and lymphatic system disorders | Febrile neutropenia, Neutropenia | Anaemia, Thrombocytopenia |
| Metabolism and nutrition disorders | Metabolic acidosis | Fluid overload |
| Psychiatric disorders | | Insomnia |
| Nervous system disorders | | Headache |
| Respiratory, thoracic and mediastinal disorders | | Epistaxis, Oropharyngeal pain |
| Gastrointestinal disorders | Stomatitis, Vomiting | Ascites, Diarrhoea, Gastrointestinal haemorrhage, Nausea |
| Hepatobiliary disorders | Hepatomegaly, Veno-occlusive liver disease | Hypertransaminasaemia |
| Skin and subcutaneous tissue disorders | | Skin exfoliation |
| Musculoskeletal and connective tissue disorders | | Back pain, Bone pain |
| Renal and urinary disorders | | Oliguria |
| Reproductive System and Breast Disorders | Ovarian failure | |
| General disorders and administration site conditions | | Pyrexia |
| Investigations | | Alanine aminotransferase increased, Aspartate aminotransferase increased, Aspergillus test positive |
\*\\* Based on 29 patients who have undergone myeloablative conditioning by busulfan in the\* integrated \*data set.\*
\*\*Description of selected adverse reactions\*\*
\*Presence of Anti ARSA Antibodies\*
Five out of 35 patients tested positive for anti-ARSA antibodies (AAA) at various post-treatment time points and had the event “Antibody test positive / Presence of antibodies against arylsulfatase A” reported by the Investigator.
Antibody titres were generally low and resolved either spontaneously or after a short course of rituximab.
In all patients with positive AAA test results, no negative effects were observed in the post-treatment ARSA activity of peripheral blood or bone marrow cellular subpopulations nor in the ARSA activity within the cerebrospinal fluid.
Patients treated with Libmeldy should be regularly monitored for AAA (see section 4.4).
\*Peripheral blood mobilisation and apheresis\*
During the clinical studies, haematopoietic stem cell collection was performed either through bone marrow (BM) harvest or peripheral blood mobilisation. The safety profile of BM harvest and mobilisation/apheresis were consistent with the known safety and tolerability of both procedures and the SmPC of mobilisation agents (G-CSF and plerixafor).
No serious adverse events were reported as potentially attributable to BM harvest within the range of BM volumes harvested (median volume was 35.5 mL/kg; range: 15.1-56.4 mL/kg). In the Integrated Safety Set (n=29), one patient experienced bone pain, which was qualified as a grade 2 adverse event and deemed related to the BM harvest procedure, but unrelated to the volume harvested.
No serious adverse events were reported as potentially attributable to mobilisation and apheresis and none of the patients who underwent mobilisation experienced any adverse events in the pre-treatment phase which could have been attributed to the mobilising agents.
\*\*Reporting of suspected adverse reactions\*\*
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.4.9 Overdose
No data from clinical studies are available regarding overdose of Libmeldy.
## Pharmacological Properties
5.1 Pharmacodynamic properties
Pharmacotherapeutic group: Other haematological agents, ATC code: A16AB21.
\*\*Mechanism of action\*\*
Libmeldy is an \*ex vivo\* genetically modified autologous CD34+ haematopoietic stem and progenitor cell (HSPC) gene therapy. Autologous CD34+ HSPCs are collected from mobilised peripheral blood (mPB) and transduced with a lentiviral vector (ARSA LVV), which inserts one or more copies of the human ARSA complementary deoxyribonucleic acid (cDNA) into the cell's genome, so that genetically modified cells become capable of expressing the functional ARSA enzyme. When administered to the patient following the administration of a myeloablative conditioning regimen, the genetically modified cells engraft and are able to repopulate the haematopoietic compartment. A subpopulation of the infused HSPCs and/or their myeloid progeny is able to migrate across the blood brain barrier to the brain and engraft as central nervous system (CNS) resident microglia and perivascular CNS macrophages as well as endoneural macrophages in the peripheral nervous system (PNS). These genetically modified cells can produce and secrete the functional ARSA enzyme, which can be taken up by surrounding cells, a process known as cross-correction, and used to break down, or prevent the build-up, of harmful sulfatides.
Following successful and stable engraftment in the patient, the effects of the product are expected to be persistent.
\*\*Pharmacodynamic effects\*\*
Durable and stable peripheral engraftment of genetically modified cells was observed from 1-month post Libmeldy administration in all evaluable patients. A persistent vector copy number (VCN) was also observed in CD34+ cells isolated from the bone marrow throughout the follow-up period. These biological findings demonstrate a sustained multilineage engraftment of gene-corrected cells, which is essential for supporting the long-term production of ARSA and resulting long-term clinical benefit.
At Year 1 post-treatment, the proportion of BM-derived colonies harbouring the LVV genome (%LV+) in the overall treated population was 54.8% (range: 20.0% to 100%, [N=23]). The proportion of BM-derived colonies harbouring the LVV genome (%LV+) at Year 5 was 45.0% (range: 18.8% to 90.6% [n=6, 4 Late infantile (LI) and 2 Early Juvenile (EJ)]), indicative of stable engraftment over time in the treated population.
Reconstitution of ARSA activity in the haematopoietic system was observed in all MLD patients treated, with a progressive reconstitution of ARSA levels in Peripheral Blood Mononuclear Cells (PBMCs) which reached values within the normal reference range by 3 months post-treatment and remained stable within or above the normal range throughout the duration of the follow-up (see Figure 1).
\*\*Figure 1 ARSA activity in PBMCs over time (geometric mean and 95% CIs), by disease subtype (integrated efficacy set; N=29)\*\*
Note: Values < LLQ are imputed at LLQ. LLQ is 25.79 nmol/mg/h. GMs and 95% CIs are presented where there are at least 3 patients with non-missing data. ARSA: arylsulfatase A; CI: confidence interval; GM: geometric mean; LLQ: lower limit of quantification; PBMCs: peripheral blood mononuclear cells.
ARSA activity was also measured in cerebrospinal fluid (CSF) as a surrogate compartment of metabolic correction in the brain. The ARSA activity in CSF went from undetectable at Baseline to detectable in all evaluable patients by Month 6 post-treatment and reached reference range levels at Year 1 post-treatment. Thereafter, central reconstitution of ARSA enzymatic activity remained stable within the reference range.
\*\*Clinical efficacy\*\*
Clinical efficacy was based on the integrated analysis of results from 29 early-onset MLD patients treated with Libmeldy prepared as a fresh (non-cryopreserved) formulation. These results were generated in twenty (20) patients treated in the Registrational Study (Study 201222 - an open-label, non-randomized, single-arm safety and efficacy clinical trial) with a median duration of post-treatment follow-up of 4.0 years (range: 0.6 to 7.5 years) and nine (9) patients treated in the context of 3 expanded access programs with a median follow-up of 1.5 years (range: 0.99 years to 2.72 years).
In addition, initial results from 9 patients treated in a further study with the commercial (cryopreserved) formulation of Libmeldy (Study 205756) are summarised below.
The MLD disease spectrum can present in a variety of clinical forms, primarily based on the age of onset of the first symptoms of the disease. Pre-symptomatic Late Infantile (LI) or Early Juvenile (EJ) MLD patients and early symptomatic EJ MLD patients with biallelic mutations in the ARSA gene leading to a reduction of the ARSA enzymatic activity were included in the clinical development of Libmeldy. 'Biallelic mutations leading to a reduction of the ARSA enzymatic activity' refers to mutations leading to partial or total disruption of the ARSA enzymatic activity and resulting in accumulation of sulfatides. These biallelic mutations exclude common neutral mutations described in association with ARSA pseudo-deficiency alleles.
\*Patients and disease characteristics\*
The MLD forms (variants) were defined by the presence of the following criteria during the clinical development:
• Late infantile (LI): age at onset of symptoms in the older sibling(s) ≤30 months and/or 2 null (0) mutant ARSA alleles and/or peripheral neuropathy at electroneurography (ENG) study.
• Early juvenile (EJ): age at onset of symptoms (in the patient or in the older sibling) between 30 months and before 7 years, and/or 1 null (0) and 1 residual (R) mutant ARSA allele(s) and/or peripheral neuropathy at ENG study.
In the above definition, null (0) or residual (R) alleles refer to either known or novel mutations.
The symptomatic status of the patients was defined as follows:
• Pre-symptomatic: at time of inclusion into the clinical studies, LI or EJ patients were without neurological impairment (disease-related symptoms), with or without signs of the disease revealed by instrumental evaluations i.e. electroneurographic study (ENG) and brain magnetic resonance imaging (MRI).
Based on an analysis of the baseline characteristics of pre-symptomatic LI and EJ patients treated during the clinical development program, the definition of pre-symptomatic status was further refined to maximise the treatment benefit.
Taking the results of this analysis into account, treatment with Libmeldy of a pre-symptomatic patient should be considered:
- For a patient with the LI form of the disease, in the absence of a delay in achievement of independent standing, or a delay in achievement of independent walking, associated with abnormal signs at neurological evaluation.
- For a patient with the EJ form of the disease, in the absence of neurological signs or symptoms of the disease resulting in cognitive, motor, or behavioural functional impairment or regression (substantiated by neurological examination, gross motor function evaluation and/or age appropriate neuropsychological tests).
- Early symptomatic: at time of inclusion into the clinical studies, early symptomatic EJ patients met the following 2 criteria: intelligence quotient (IQ) ≥70 and the ability to walk independently for ≥ 10 steps.
Based on the analysis of clinically relevant benefits on the motor and cognitive functions, efficacy was only demonstrated in patients treated before the onset of cognitive deterioration at a time when they were still able to walk independently.
Taking these results into consideration, treatment with Libmeldy of a patient with an early-symptomatic EJ form of the disease should be considered:
- If this patient is able to walk independently, which means that the patient's GMFC-MLD score is ≤ 1, and
- If the patient's cognitive function has not started declining, which means that the patient's IQ is ≥ 85.
At time of inclusion in the clinical studies, out of the 29 early-onset MLD patients, 20 were pre-symptomatic and 9 were early symptomatic, 16 had a diagnosis of LI MLD and 13 had a diagnosis of EJ MLD. All LI study patients and some EJ patients were identified after an older sibling had developed symptoms and received an MLD diagnosis, prompting testing in other family members.
\*\*Table 3\*\* \*\*Summary of demographic characteristics by symptomatic status at time of gene therapy and by disease subtype (Integrated efficacy set)\*\*
| | | | | |
| --- | --- | --- | --- | --- |
| | \*\*Pre-symptomatic patients\*\* | | \*\*Early symptomatic patients\*\* | |
| \*\*Late Infantile subgroup (N=15)\*\* | \*\*Early Juvenile subgroup (N=5)\*\* | \*\*Late Infantile subgroup (N=1)\*\* | \*\*Early Juvenile subgroup (N=8)\*\* |
| \*\*Sex, n (%)\*\* | | | | |
| Female | 5 (33) | 2 (40) | 1 (100) | 5 (63) |
| Male | 10 (67) | 3 (60) | 0 | 3 (38) |
| \*\*Age at GT, in months\*\* | | | | |
| Median | 13.1 | 48.9 | 23.3 | 77.9 |
| Min | 7.6 | 11.4 | 23.3 | 38.8 |
| Max | 17.8 | 66.8 | 23.3 | 139.9 |
\*Mobilisation and apheresis\*
During the clinical development, all (ten) patients for whom the decision was made to use mPB as the source material – and not to conduct a BM harvest - were administered G-CSF (10-12.5 μg/kg/day) to mobilise CD34+ cells prior to the apheresis procedure. Starting from day 3 of G-CSF administration, an additional mobilising agent, plerixafor, was given once daily (0.24 mg/kg, subcutaneous) if clinically indicated depending on the white blood cells and CD34+ cell count in the patient's peripheral blood. Apheresis was performed as soon as the CD34+ cell count reached an adequate level, according to standard procedures.
If the target number of collected CD34+ cells to manufacture Libmeldy and to provide the back-up transplant were not reached with a single apheresis, a second procedure was performed. For all patients, the minimum number of CD34+ cells to manufacture Libmeldy (8 x 106 CD34+ cells/kg) was collected with 1 cycle of mobilisation and 1 or 2 apheresis.
\*Pre-treatment conditioning\*
All patients received systemic conditioning with busulfan prior to treatment with Libmeldy.
Thirteen patients (45%) were treated with a sub-myeloablative conditioning (SMAC) regimen, defined as a target cumulative AUC of 67,200 μg\\*h/L. Sixteen patients (55%) were treated with a myeloablative (MAC) conditioning regimen, defined as a target cumulative AUC of 85,000 μg\\*h/L.
For the SMAC conditioning regimen, patients received a total of 14 doses of busulfan (according to patient's weight), as a 2-hour IV infusion administered every 6 hours from Day -4 to Day -1. Busulfan plasma levels were monitored by serial pharmacokinetic sampling and adjusted using a target dose AUC of 4800 μg\\*h/L (range: 4200 to 5600 μg\\*h/L), which corresponds to an expected total cumulative AUC of 67,200 µg\\*h/L (range 58,800 to 78,400 μg\\*h/L). The average, cumulative AUC in patients who received a SMAC regimen was higher than expected but remained within the target range (geometric mean 71,923.53 [95% CI: 68,751.04, 75,242.41]).
For the MAC conditioning regimen, patients received body-surface area-based dosing of busulfan according to the patients age (80 mg/m2/dose if ≤ 1year; 120 mg/m2/dose if >1 year) for a total of 4 doses, administered as a 3 hour IV infusion every 20 to 24 hours from Day -4 to Day -1. Busulfan plasma levels were monitored by serial pharmacokinetic sampling and adjusted using a target total cumulative AUC of 85,000 µg\\*h/L (range: 76,500 to 93,500 µg\\*h/L).
Subgroup analyses by conditioning regimen i.e. comparison of the subgroups of patients who received the MAC vs. the SMAC regimen, didn't show noticeable differences in the level of transduced cell engraftment nor in ARSA enzyme activity (in total PBMCs and BM-derived mononuclear cells). Moreover, the safety profiles of both regimens were shown to be comparable.
Therefore, the decision to use the MAC or SMAC regimen for pre-treatment conditioning is at the discretion of the treating physician, taking into consideration the patient's clinical characteristics such as, but not limited to, age, hepatic function, prematurity and thrombophilia.
During clinical development, prophylaxis for veno-occlusive disease (VOD) and related endothelial injury complications was required per institutional practice with ursodeoxycholic acid or defibrotide.
\*Libmeldy administration\*
All patients (N=29) were administered the medicinal product with a mean (min, max) cell dose of 10.81 x 106 (4.2, 25.9) CD34+ cells/kg as an intravenous infusion.
\*Integrated efficacy results (N=29)\*
The co-primary efficacy endpoints were:
• Gross Motor Function Measure (GMFM): An improvement of >10% of the total GMFM score in treated patients, when compared to the GMFM scores in the age-matched, untreated historical control MLD population (i.e., TIGET natural history [NHx] Study), evaluated at Year 2 after treatment (see Table 4), and
• ARSA activity: A significant (≥2 SD) increase in residual ARSA activity as compared to pre-treatment values, measured in peripheral blood mononuclear cells (PBMC) at Year 2 after treatment (see Pharmacodynamic Effects, Figure 1 and Table 5).
Early-onset MLD patients treated before the onset of overt symptoms showed normal motor development, stabilisation, or delay in the rate of progression of motor dysfunction as measured by GMFM total score (%) (see Table 4).
Using an ANCOVA model adjusted for age at GMFM assessment and treatment, the mean difference between treated pre-symptomatic LI patients and age matched untreated LI patients from the NHx study was 71.0% at Year 2 and 79.8% at Year 3. Similarly, the mean difference between treated pre-symptomatic EJ patients and aged matched untreated EJ patients was 52.4% at Year 2 and 74.9% at Year 3. These treatment differences were statistically significant (p≤0.008) in favour of Libmeldy.
Although not statistically significant, a clear difference in GMFM total score was also noted between treated early symptomatic EJ patients and aged matched untreated EJ patients (28.7% at Year 2; p=0.350 and 43.9% at Year 3; p=0.054).
\*\*Table 4 GMFM total score (%) at Year 2 and Year 3 in pre-symptomatic and early-symptomatic patients (late infantile and early juvenile subgroups) with comparison to age-matched natural history data (integrated efficacy set).\*\*
| | | | | |
| --- | --- | --- | --- | --- |
| | | \*\*Adjusted mean GMFM total score\*\* | | \*\*Mean treatment difference in GMFM total score between treated patients and age-matched untreated natural history patients\*\* |
| \*\*Treated patients\*\* | \*\*Untreated natural history patients\*\* |
| \*\*Pre-symptomatic patients\*\* | \*\*Late infantile\*\* | | | |
| \*\*Year 2\\*\*\* | 79.5% (n=10) | 8.4% (n=8) | 71.0% (95% CI: 60.4 – 81.7); p<0.001 |
| \*\*Year 3\*\* | 82.6% (n=9) | 2.8% (n=9) | 79.8% (95% CI: 66.2 – 93.3) p<0.001 |
| \*\*Early juvenile\*\* | | | |
| \*\*Year 2\\*\*\* | 96.7% (n=4) | 44.3% (n=8) | 52.4% (95% CI: 25.1 – 79.6); p=0.008 |
| \*\*Year 3\*\* | 93.2% (n=4) | 18.2% (n=9) | 74.9% (95% CI: 50.8 – 99.1); p<0.001 |
| \*\*Early Symptomatic patients\*\* | \*\*Early juvenile\*\* | | | |
| \*\*Year 2\\*\*\* | 60.7% (n=6) | 31.9% (n=10) | 28.7% (95% CI: -14.1 – 71.5); p=0.350 |
| \*\*Year 3\*\* | 59.8% (n=6) | 15.9% (n=10) | 43.9% (95% CI: 9.2 – 78.5); p=0.054 |
\\* The Gross Motor Function Measure at two years after treatment was a co-primary endpoint of the registrational clinical study. Note: Analysis of covariance adjusting for treatment and age. P-values are from a two-sided 5% hypothesis test with null hypothesis of 10% difference. CI: confidence interval; EJ: early juvenile; GMFM: gross motor function measurement; LI: late infantile; MLD: metachromatic leukodystrophy.
Deterioration of gross motor function was assessed from disease onset in EJ patients who were early-symptomatic at the time of gene therapy. By four years post disease onset, the estimated proportion of patients who survived and maintained locomotion and ability to sit without support (GMFC-MLD level 5 or higher) was 62.5% in the treated group compared to 26.3% in the untreated group, representing a delay in disease progression following treatment with Libmeldy.
A statistically significant increase in ARSA activity in PBMCs was also observed at Year 2 post-treatment compared to pre-treatment baseline in both pre-symptomatic patients (20.0-fold increase; p<0.001) and early symptomatic patients (4.2-fold increase; p=0.004) (See Table 5).
\*\*Table 5 ARSA activity measured in PBMCs (geometric mean) at Baseline and Year 2 after treatment in pre-symptomatic and early-symptomatic patients (integrated efficacy set).\*\*
| | | | |
| --- | --- | --- | --- |
| | \*\*Geometric mean (%CVb)\*\* \*\*ARSA Activity in PBMCs\*\* | | \*\*Fold Increase from Baseline to Year 2 \\*\*\* |
| \*\*Baseline\*\* | \*\*Year 2\*\* |
| \*\*Pre-symptomatic\*\* | 26.923 (16.72) (n=19) | 339.736 (270.85) (n=14) | 20.0 (95% CI: 9.0, 44.0) p<0.001 |
| \*\*Early-symptomatic\*\* | 26.025 (2.72) (n=9) | 134.056 (55.94) (n=6) | 4.2 (95% CI: 1.6, 11.2) p=0.004 |
\\* Ratio in adjusted means from a mixed model repeated measures of data on the log scale, adjusting for visit, baseline, baseline by visit interaction, disease subtype and disease subtype by visit interaction
A secondary efficacy endpoint of the integrated efficacy analysis was measurement of IQ above 55 post-treatment with Libmeldy, the threshold for moderate mental retardation (DSM-IV), using neuropsychological tests. Intelligence Quotient/Development Quotient (IQ/DQ) measures, i.e. cognitive and language abilities, complement results from the GMFM and provide further evidence that the high levels of engraftment and enzymatic reconstitution translate into relevant treatment effects on key symptomatic domains in MLD patients.
In the LI subgroup (all pre-symptomatic at time of treatment except one), 12 out of 15 assessed patients had a fairly constant IQ/DQ, within the normal range (IQ/DQ score of 100 +/- SD of 15) throughout follow-up. All but 2 of these patients (one pre-symptomatic, one early-symptomatic) remained above the threshold of severe mental disability (IQ/DQ >55) at chronological ages at which all 14 untreated NHx patients with neuropsychological assessments showed evidence of severe cognitive impairment (i.e. IQ/DQ below 55 and close to 0).
Of the 10 surviving EJ patients, all 4 pre-symptomatic patients and 4 out of 6 early-symptomatic patients showed normal IQ/DQ throughout follow-up. In contrast, 11 out of 12 NHx patients with neuropsychological assessments showed evidence of severe cognitive impairment during follow-up.
At the time of the integrated data analysis, i.e. at a median follow-up time of 3.035 years post-treatment (range 0.99 to 7.51), none of the 16 patients in the treated LI subgroup, all pre-symptomatic at time of treatment except one, had died (100% overall survival). Four pre-symptomatic LI patients were alive 6 or more years after treatment and 2 pre-symptomatic LI patients were alive 7 or more years after treatment. In comparison, 12 out of 19 (63.2%) untreated LI patients in the NHx study had died at the time of the analysis.
Comparable overall survival was observed in the treated and untreated EJ groups with a median follow-up time of 3.49 years post-treatment (range 0.64 to 6.55). One out of 5 (20%) EJ patients treated at pre-symptomatic stage died, due to cerebral ischemic infarction, not deemed related to Libmeldy. There were 2 deaths among the 8 (25.0%) EJ patients treated at early-symptomatic stage, both due to disease progression, and also not considered to be related to Libmeldy treatment. Similarly, 3 of the 12 (25%) untreated EJ patients in the NHx study had died at the time of the analysis.
A sensitivity analysis conducted to identify clinical factors, which could have influenced the level of treatment benefit with Libmeldy and optimize the recommended use of the treatment, identified 4 treatment failures:
- One LI patients experienced onset of disease-related symptoms between screening and administration of Libmeldy and was considered symptomatic at the time of treatment. The progression of this patient post-treatment was comparable to untreated NHx patients in both cognitive function and motor development.
- Three early symptomatic EJ patients treated with Libmeldy showed deterioration in both motor and cognitive functions comparable to that observed in untreated NHx patients and progression of the disease led to death in two of them. Two out of the three patients showed IQ<85 (82 and 58) at the time of treatment. Two out of the three patients showed deterioration between screening and baseline (onset of conditioning regimen) assessments.
\*Study 205756 (cryopreserved commercial formulation)\*
Study 205756 is an open-label, single-arm study to evaluate the cryopreserved (commercial) formulation of Libmeldy in the treatment of pre-symptomatic LI and pre-symptomatic and early symptomatic EJ MLD patients. The cell dose range used in the first 9 patients in Study 205756 (10.45-30.0 x 106 CD34+ cells/kg) is close to the range used in patients treated with the fresh (investigational) formulation of the medicinal product (4.2-25.9 x 106 CD34+ cells/kg).
At the time of data cut, 6 patients (3LIs, 3EJs), all pre-symptomatic at the time of treatment, have been treated, with a median follow-up post-treatment of 0.87 year (range: 0.0 to 1.47 years). Preliminary efficacy data show levels of engraftment, Vector Copy Number, ARSA activity in PBMCs and CSF at different timepoints post-gene therapy within the range observed in the integrated data analysis of the patients treated with the fresh formulation of Libmeldy.
Preliminary safety data indicate that Libmeldy was well tolerated. The safety profile observed in this study with the cryopreserved formulation is consistent with the profile established in patients treated with the fresh formulation in terms of nature, time of onset and frequency of reported adverse events.
\*Paediatric population\*
Libmeldy has been studied in infants and children with an age range between 7.6 months and 11.6 years.
The European Medicines Agency has deferred the obligation to submit the results of studies with Libmeldy in the late juvenile subset of the paediatric population with metachromatic leukodystrophy (i.e. MLD patients aged between 7 and less than 17 years at time of disease onset) (see section 4.2 for information on paediatric use).5.2 Pharmacokinetic properties
Libmeldy is a gene therapy medicinal product consisting of autologous cells that have been genetically modified \*ex vivo\*. The nature of Libmeldy is such that conventional studies on pharmacokinetics, absorption, metabolism, and elimination are not applicable. The biodistribution of Libmeldy was nonetheless studied and distribution to haematopoietic tissues and disease target organs (including the brain) was demonstrated.5.3 Preclinical safety data
Due to the nature of Libmeldy, a standard toxicological assessment was not applicable and conventional mutagenicity, carcinogenicity and reproductive and developmental toxicity studies have not been conducted.
The pharmacology, toxicology and genotoxicity of Libmeldy were evaluated \*in vitro\* and in \*vivo\*. Integration site analysis (ISA) of mouse Lin- bone marrow cells and human CD34+ cells transduced with ARSA LVV was conducted pre- and post-transplantation into mice and showed no enrichment for insertion in or near cancer-related genes, or clonal dominance. A prototype lentiviral vector related to ARSA LVV did not induce \*in vitro\* transformation and sustained growth of transduced wild type mouse Lin- bone marrow cells due to insertional transformation. Lin- bone marrow cells from Cdkn2a-/- mice, a strain prone to cancer triggered by gamma-retroviral insertional mutagenesis, transduced with the same prototype lentiviral vector did not show genotoxic potential when transplanted into wild type mice.
Toxicity and oncogenesis (tumorigenicity) studies were performed in the mouse model of MLD. No evidence of toxicity due to ARSA overexpression and no abnormal or malignant growth of transplanted cells or haematopoietic tumours related to the integration of ARSA LVV were observed. ARSA overexpression in human HSPCs and in ARSA Tg mice did not impair the activation of other sulfatases dependent on the sulfatase activator SUMF-1, did not affect the proliferation and differentiation capacities of transduced cells and did not induce toxicity or functional impairment in ARSA Tg mice.
Additional studies with human CD34+ cells transduced with ARSA LVV administered to immunodeficient, myeloablated mice demonstrated no toxicity, no vector mobilisation and bystander transduction of male gonads.
Molecular monitoring did not detect replication competent lentivirus (RCL).
## Pharmaceutical Particulars
6.1 List of excipients
Dimethylsulfoxide
Sodium chloride
Human albumin6.2 Incompatibilities
In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.6.3 Shelf life
6 months.
Once thawed: maximum 2 hours at room temperature (20 °C-25 °C).6.4 Special precautions for storage
Keep the infusion bag(s) in the metal cassette(s).
Libmeldy must be stored in the vapour phase of liquid nitrogen (< -130 °C) and must remain frozen until the patient is ready for treatment to ensure viable cells are available for patient administration. Thawed medicinal product should not be refrozen.
For storage conditions after thawing of the medicinal product, see section 6.3.6.5 Nature and contents of container
50 mL ethylene vinyl acetate (EVA) infusion bag(s) with two available spike ports, packed in an EVA overwrap bag placed inside a metal cassette.
Libmeldy is shipped from the manufacturing facility to the treatment centre storage facility in a cryoshipper, which may contain multiple metal cassettes intended for a single patient. Each metal cassette contains one infusion bag of Libmeldy.6.6 Special precautions for disposal and other handling
\*\*Precautions to be taken before handling or administering the medicinal product\*\*
• This medicinal product contains human blood cells. Healthcare professionals handling Libmeldy must take appropriate precautions (wearing gloves, protective clothing and eye protection) to avoid potential transmission of infectious diseases.
• Libmeldy must remain at <-130 °C at all times, until the content of the bag is thawed for infusion.
\*\*Definition of the dose to be administered\*\*
• Considering the posology information provided in section 4.2, the dose to be infused and number of infusion bags to be used should be defined based on the total number of CD34+ cells supplied indicated on the Lot Information Sheet (i.e. the 'supplied dose', calculated based on patient's weight at time of cell harvest). The dose of Libmeldy to be administered should also take into account the patient's weight at the time of treatment, and the fact that any bag used should be administered in its entirety.
• Careful consideration must be given to the volume of infusion in relation to age and weight of the patient. When the dose of Libmeldy to be infused represents more than one bag, it should be ensured prior to infusion that the volume of medicinal product to be infused is compatible with the recommended limit of DMSO, i.e. the total volume of DMSO administered should remain <1% of the patient's estimated plasma volume. Therefore, the maximum volume of Libmeldy to be administered should remain < 20% of the patient's estimated plasma volume.
• The following graph is provided as a reference in order to determine the maximum volume of Libmeldy which can be infused to a patient based on their estimated plasma volume.
\*\*Figure 2 Guidance on DMSO safety limit: the maximum volume of Libmeldy to be administered should remain < 20% of the patient's estimated plasma volume.\*\*
\*\*Preparation\*\* \*\*prior to administration\*\*
• A patient may have multiple infusion bags. Each infusion bag is provided inside an overwrap bag, which is contained in a metal cassette.
• The overwrapped infusion bag(s) must be kept inside the metal cassette(s) in the vapour phase of liquid nitrogen at < -130 °C until ready to thaw and infuse.
• Account for all infusion bags and confirm each infusion bag is within the expiry date using the accompanying Lot Information Sheet.
• Sterile sodium chloride 9 mg/mL (0.9%) solution for injection should be available to prime the tubing prior to infusion, and to flush the infusion bag and tubing after infusion.
\*\*Checking prior to thawing\*\*
• Do not remove the metal cassette from cryogenic storage or thaw Libmeldy until the patient is ready to be infused. The timing of thaw of the infusion bag(s) containing Libmeldy and of the infusion should be coordinated. Confirm the infusion time in advance and adjust the start time for thaw so that the treatment is available for infusion when the patient is ready.
• Open the metal cassette and inspect the overwrap bag and infusion bag for any breaches of integrity before thawing. If an infusion bag is compromised, follow the local guidelines for handling of waste of human-derived material and contact Orchard Therapeutics immediately.
• Prior to thawing Libmeldy, it must be verified that the patient identity matches the unique patient information reported on the packaging labels and on the accompanying Lot Information Sheet. Libmeldy is intended solely for autologous use. Do not thaw or infuse Libmeldy if the information on the patient-specific label on the infusion bag does not match the intended patient.
\*\*Thawing\*\*
• After careful removal from the metal cassette, thaw the infusion bag in its sealed overwrap bag at 37 °C in a controlled thawing device until there is no visible ice in the infusion bag.
• Once thawing is complete, the bag should be removed immediately from the thawing device.
• The overwrap bag should be carefully opened to remove the infusion bag which should be kept at room temperature (20 °C-25 °C) until infusion.
• Gently massage the infusion bag to resuspend the cells. The content of the infusion bag should be inspected for any remaining visible cellular aggregates. Small clumps of cellular material should disperse with gentle manual mixing. Do not shake the bag.
• The infusion bag should not be washed, spun down, sampled and/or resuspended in new media prior to infusion.
• Libmeldy should not be irradiated as irradiation could lead to inactivation of the product.
• If more than one infusion bag is provided for the patient treatment dose, the next bag should only be thawed after the content of the preceding bag has been fully infused.
\*\*Administration\*\*
• Libmeldy should be administered as an intravenous infusion via a central venous catheter, per the administration site's standard procedures for cell therapy products.
• The recommended administration set consists of a blood transfusion set equipped with a 200µm filter.
• Each bag should be infused by gravity within 2 hours of thaw, including any interruption during the infusion, to maintain maximum product viability.
• The maximum infusion rate is 5 mL/kg/h, and the content of each bag should be infused within approximately 30 minutes.
• When more than one bag of Libmeldy is needed, only one bag of product should be infused per hour.
• Patients not previously exposed to DMSO should be observed closely. Vital signs (blood pressure, heart rate, and oxygen saturation) and the occurrence of any symptom should be monitored for up to 3 hours following the infusion.
• At the end of the infusion, flush all Libmeldy remaining in the infusion bag and any associated tubing with sodium chloride 9 mg/mL (0.9%) solution for injection to ensure that as many cells as possible are infused into the patient. Careful consideration must be given to the volume of infusion in relation to the age and weight of the patient.
\*\*Measures to take in case of accidental exposure\*\*
• In case of accidental exposure local guidelines on handling of human-derived materials must be followed. Work surfaces and materials which have potentially been in contact with Libmeldy must be decontaminated with appropriate disinfectant.
\*\*Precautions to be taken for the disposal of the medicinal product\*\*
• Unused medicinal products and all material that have been in contact with Libmeldy (solid and liquid waste) should be handled and disposed of as potentially infectious waste in accordance with local guidelines on handling human-derived material.
